Drug deposition and distribution in healthy and atherosclerotic arteries and in models of atherosclerosis following bulk or stent-based drug delivery by Vukmirovic, Neda
Drug Deposition and Distribution in Healthy and Atherosclerotic




M.S., Chemical Engineering, MIT, 2000
B.S., Chemical Engineering, Oregon State University, 1997
SUBMITTED TO THE HARVARD-MIT DIVISION OF HEALTH SCIENCES AND
TECHNOLOGY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE
DEGREE OF
DOCTOR OF PHILOSOPHY
in the subject of
MEDICAL ENGINEERING AND MEDICAL PHYSICS
AT THE




C 2007 Neda Vukmirovic. All rights reserved.
The author hereby grants permission to MIT to reproduce and to distribute publicly paper and
electronic copies of this thesis document in whole or in part.
Signature of Author: • ..
Division of Health Sciences and Technology
May 10, 2007
Certified by:
Elazer R. Edelman, M.D., Ph.D.
Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology
Thesis Supervisor
Accepted by: . ,
I Martha L. Gray, Ph.D.
Edward Hood Taplin Professdr of Medical and Electrical Engineering
MASSACHUSETTS INSTITUTE Director, Harvard-M.I.T. Division of Health Sciences and Technology
OF TECHNOLOGY




Drug Deposition and Distribution in Healthy and Atherosclerotic
Arteries and in Models of Atherosclerosis Following Bulk or Stent-
Based Drug Delivery
by Neda Vukmirovic
Submitted to the Harvard-MIT Division of Health Sciences and Technology on May 10, 2007, in partial
fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Medical
Engineering and Medical Physics.
Abstract
Drug eluting stents have revolutionized the practice of medicine and the landscape of medical
devices. Yet, more than four years after introduction clinical trial data and clinical use have still
not fully clarified what drives the safety and efficacy of these devices. The goal of this thesis
was to help fill this void by describing the mechanisms by which stent-eluted drugs are
distributed within healthy and atherosclerotic vascular models.
In the first part of the thesis we investigated the effect of drug physicochemical properties on
drug deposition, retention, and distribution in a healthy vascular model. We found that
hydrophobic drugs are deposited to a far greater degree than hydrophilic drugs, with longer
retention times, and distribution patterns that likely track with specific and general binding sites.
The second part of the thesis investigated how arterial ultrastructure in health and disease
modulates the arterial deposition and distribution of hydrophobic antiproliferative drugs used
with drug-eluting stents. We tracked the distribution of radiolabeled and FITC-labeled
compounds and demonstrated that macrostructural changes in arterial architecture led to
profound changes in drug deposition. Paclitaxel in particular was sensitive to tissue state. This
drug binds specifically to tubulin and to lesser extent in a general manner to elastic. Drug levels
fell as paclitaxel, tubulin and elastin were displaced by lipid and collagen. These observations
might well explain how drugs may partition within different arterial lesions as determined by
lesion composition.
Finally, we demonstrated that association with these binding sites was governed by association
kinetics that reflects the different components of the arterial wall compartments. Slower release
kinetics yielded up to 64% higher deposition of a drug from stents implanted in rabbit iliac
arteries over a 28-day period. Mathematical modeling illustrates that the dependence of drug
deposition on stent release kinetics is contingent on drug retention. Further model development is
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CHAPTER 1: Background and Research Significance
1.1 Cardiovascular Disease and Atherosclerosis
Statistics
In 2004, about 79 million Americans had one or more forms of cardiovascular disease (CVD),
which included high blood pressure, coronary heart disease (CHD), and stroke [1] [24].
Cardiovascular disease claims more lives each year than the next 4 leading causes of death
combined, which are cancer, chronic lower respiratory diseases, accidents, and diabetes mellitus
[25]. In 2004, CVD claimed 871,500 lives. CHD claimed 452,300 lives and is the single leading
cause of death in America today [24]. The estimated direct and indirect cost of CVD for 2006
was $403.1 billion, and for CHD $142.5 billion [25].
Biological Basis
To understand the basis of CVD it is necessary to consider the structure of the blood vessel wall,
as shown in Figure 1 [7].
The blood vessel wall consists of three layers: the intima, media, and adventitia. The intima is
the innermost layer and contains the endothelial cells. Its dividing line with the media is a layer
of elastin (internal elastic lamina). The media is made up of smooth muscle cells, a varied
number of elastic sheets, bundles of collagenous fibrils, and a network of elastic fibrils. Its
dividing line with the adventitial is a layer of elastin (external elastic lamina). The adventitial
layer contains collagen fibers, ground substances, and some fibroblasts, macrophages, blood
vessels (vasa vasorum), myelinated and nonmyelinated nerves.
Pathology
Well-recognized cardiovascular risk factors (hypertension, dyslipidemia , diabetes, smoking,
prior or family history of CVD, age, sex, obesity and physical inactivity) are associated with
endothelial injury and changes in the vessel wall that lead to cardiovascular disease and clinical
events. One of the earliest changes associated with these risk factors is an increase in oxidative
stress in the vessel wall. This causes endothelial cells to decrease production of some compounds
and increase production of others [8]. For example, production of nitric oxide (NO), a powerful
vasodilator, is decreased. Production of vasoconstrictors, notably endothelin and angiotensin II,
is increased. Greater production of local mediators (e.g., vascular cell adhesion molecule,
VCAM, and plasminogen activator inhibitor 1, PAI-1) promotes inflammation, disrupts
fibrinolysis, and at later stages of disease increases vascular remodeling and plaque rupture. The
vascular endothelium secretes numerous other substances that modulate blood vessel tone and
participate in the development and progression of atherosclerosis.
Atherosclerosis
Coronary heart disease (CHD) is caused by atherosclerosis, which is a multifactorial disease that
affects the intima of elastic arteries and manifests itself in progressive narrowing and hardening
of the arteries over time. The disease is characterized by intramural deposits of lipids,
proliferation of vascular SMCs (smooth muscle cells) and fibroblasts, and accumulation of
macrophages. These changes are accompanied by a calcification of arterial wall, loss of
elasticity of vessel wall, and narrowing or dilatation of the vascular lumen (Figure 2, [11]).
Atherosclerosis is responsible for more disability and death than any other disease (95% of
deaths from coronary artery disease, about 50% of deaths from diabetes and about 50% of those
from cerebrovascular disease [9]). The disease is commonly seen in the aorta, but also
frequently found in the smaller arteries such as the coronaries and the cerebrals and to a lesser
extent in the medium-sized vessels.
Coronary atherosclerosis is clinically the most important aspect of atherosclerosis. Coronary
arteries are relatively narrow, and atherosclerosis could seriously reduce the blood flow through
them. Slow, progressive narrowing of the arterial lumen that occurs over an extended period
causes myocardial hypoxia and presents clinically either as angina pectoris (prolonged
substernal, thoracic pain) or congestive heart failure (a condition where the heart is failing to
pump efficiently, which often results in congestion in the lungs). Sudden occlusion of a
coronary artery by a thrombus formed over an ulcerated atheromas causes myocardial infarct.
Pathogenesis of Atherosclerosis
The pathological effects of atherosclerosis occur over decades, through several stages of disease
progression, from early fatty streaks to advanced lesions (found beginning in the fourth decade
of life) and clinical events. According to the response to injury hypothesis [12], Figure 3, the
pathogenesis of atherosclerosis begins with an infiltration of lipid into the vessel wall. A subtle
injury to the endothelium initiates the process [10] by injuring the impermeable endothelial layer.
This allows small pools of extracellular lipid to form within smooth muscle cell layers,
disrupting the intimal lining of the vessel. This is accompanied by attachment of monocytes and
platelets to the internal surface of the artery and local thrombus formation. These changes alter
the permeability of the arterial wall, facilitating even more influx of lipids.
The principal lipids, which accumulate in the intima are cholesterol and its esters. In the free
state these substances are insoluble in the body fluids, and when introduced into connective
tissue excite a "foreign-body" type of tissue reaction, or an inflammatory reaction, where
scavenger monocytes infiltrate the intima, transforming into macrophages that phagocytose lipid-
laden fragments of damaged cells and stroma. Macrophages that have accumulated lipid in their
cytoplasm appear histologically as foam cells, or microscopically as a fatty streak.
Macrophages secrete growth factors and cytokines, which recruit additional monocytes,
macrophages, and other cells. Cytokines and growth factors also stimulate the proliferation of
smooth muscle cells and their ingrowth into the intima from the tunica media. Lipid accumulates
not only in macrophages but also in smooth muscle cells. From dead and dying cells, cholesterol
is released into interstitial spaces. These events lead to the formation of fibro-fatty plaques and
atheromas. Atheromas consist of amorphous, lipid-rich material (lipid, cell debris, smooth
muscle cells collagen, and calcium in older persons) and are soft. On the luminal side,
atheromas are typically covered with an intimal fibrous cap, consisting of fibroblasts surrounded
by collagen, which replaces the normal intimal cells. Many atheromas undergo fibrosis
(overgrowth of' surrounding fibrous tissue/fibroblasts) and become hard plaques.
Once the plaque becomes fibrous, the danger of the plaque rupture increases. A rupture of the
protective fibrous cap permits contact between the blood and the thrombogenic material in the
lipid core of the lesion, and leads to a clinical complication that involves thrombosis. Sizable
atheromas may remain silent for decades or produce stable angina. The time of rupture will be
determined by the balance between collagen formation and its degradation by matrix
metalloproteinases (MMPs) as well as the presence of the SMCs in the fibrous cap.
Besides fibrous cap rupture, atheromas are complicated by other secondary changes, which
include calcification and ulceration, which overlie endothelium with secondary thrombosis.
1.2 History of treatments
CABG (coronary artery bypass graft) is a clinical procedure, which is done to reroute or
"bypass" the blood around a clogged coronary artery and thereby improve the supply of blood to
the heart.
PTCA (percutaneous transluminal coronary angioplasty) has been used as a less invasive and a
less expensive alternative to CABG. It is a procedure used to dilate the constricted coronary
arteries. A catheter with a deflated balloon at its tip is inserted into the narrowed part of the
artery (it is introduced into the body through an incision in the femoral artery and guided
radiographically to the coronary artery stenosis). The balloon is inflated, compressing the plaque
and enlarging the inner diameter of the blood vessel so that the blood can flow more easily.
Then the balloon is deflated and the catheter withdrawn.
Immediately after the intervention, however, there is pathobiologic responses to intervention,
which includes deposition of proteins and platelets. This is a natural response and intended to
"passivate" (i.e., render inert) the injured surface. Platelet aggregation and release of platelet-
derived growth factor (PDGF) lead to formation of a white, platelet-rich thrombus [16]. If
passivation is successful, the extent of thrombus formation is limited, leaving an adequate lumen.
However, while thrombus formation may not be significant in terms of lumen encroachment, it
serves as a locus for the second phase of repair.
The second phase is an inflammatory reaction involving mononuclear and polymorphonuclear
leukocytes, which adhere to the injury site and secrete many mediators including interleukin-1
(IL-1), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF ), and basic fibroblast growth
factor (basic FGF, [17]).
The inflammatory response stimulates smooth muscle cell migration from the media to the
intima. These cells proliferate, secrete matrix material, and become intermixed with the
monocytes. This third phase peaks approximately one week after angiography and continues for
some weeks after [17].
The final phase involves collagen deposition and remodeling of the arterial wall. Expansion of
the matrix causes progressive narrowing and (within 6 to 12 months) restenosis. The arterial wall
may expand and grow (remodel), thus facilitating maintenance of the lumen, or it may shrink and
contribute to restenosis.
Prognosis in some patients is suboptimal, as the dilated segment of the artery renarrows within
six months after the procedure, and they may require another PTCA, a stent placement, or a
coronary artery bypass surgery.
Stenting provides scaffolding for the vessel wall and was originally developed to prevent or treat
two major complications of PTCA (abrupt vessel closure and restenosis), but soon it came to be
employed in over 80% of PTCA procedures. Stents are either balloon-delivered or self-
expanding and are commonly composed of stainless steel, tantalum, or nitinol (a shape-memory
alloy of nickel and titanium). These metals are not ferromagnetic and thus do not interfere with
MRI (magnetic resonance imaging). Common stent types include coil, slotted tube, mesh and
ring, and are either made from a single strand of wire formed into a repeating pattern (coil), cut
from a single piece of metal (tube), or from overlapping wire (mesh). Each type has its own
advantages in terms of flexibility, uniform expansion, possibility of recoil, etc.
Development of new stents (Palmaz-Schatz, Crown, Multi-link, Duett, Wiktor, etc.) is evolving
rapidly. Custom-designed stents allow access to lesions that are difficult to treat. Researchers
are currently exploring the use of stents as a method of local and sustained drug delivery via
stent coatings employing biodegradable polymers, which appears to be a promising technique to
prevent restenosis (explained in the next section).
Figure 4 summarizes the rationale for stent implantation and the management of its
complications [15]. Immediately after balloon angioplasty (Figure 4a), the plaque is cracked and
irregular, and the intima is damaged. Within hours or days, the artery wall recoils (Figure 4b),
significantly narrowing the lumen. SMC (smooth muscle cells) proliferate. Later (Figure 4c),
blood cells and platelets collect at the site of intimal damage, and the SMCs migrate in,
proliferate, and form the neointima (Figure 4d). Stenting (Figure 4e) may result in a larger
vessel diameter compared to balloon angioplasty alone and may prevent early elastic recoil and
late remodeling. But it also causes vessel wall injury, which in turn leads to a proliferation of the
neointima at the stenting site. An improved revascularization strategy (Figure 4f) using a drug
coated stent reduces in-stent restenosis.
1.3 The Challenge of Restenosis met by Drug Eluting Stents
During PTCA, intraluminal balloon inflation causes dissection of the vessel wall. This leads to
restenosis in 30% to 50% of patients, likely as a result of elastic recoil of the vessel wall,
platelet-mediated thrombus formation, SMC (smooth muscle cell) proliferation, and late
remodeling. Abrupt vessel closure occurs in 4% to 10% of patients [15].
Implantation of stents (or bare metal stents) reduces abrupt closure and restenosis, leading to
improved short-term and long-term vessel patency. However, it does not limit and likely
stimulates SMC proliferation, leading to restenosis within the stent and vessel renarrowing with
the risk in the range of 15% to 20%. Subsequently, drug-eluting stents (DES) were developed.
They were designed to release pharmacological agents after deployment to inhibit the response
to injury that is mainly responsible for restenosis after BMS implantation. As a result, restenosis
and target-vessel revascularization have been reduced to rates below 10% after DES
implantation.
1.4 Motivation, Research Significance, and Hypothesis
Motivation
Many pharmacological agents considered for DES have been tested in animal models and have
been effective. For example, animal studies have shown that drugs like paclitaxel inhibit cell
proliferation and intimal hyperplasia following balloon angioplasty and stent implantation [19,
20]. However, the mechanism by which drugs distribute within atherosclerotic lesions and act to
inhibit restenosis are not precisely known. Moreover, many of the agents, which have been
successful in animal trials have been ineffective in human clinical trials [21]. This disparity in
results between animal-model research and clinical trials has led to skepticism about the validity
of animal models in restenosis research.
However, whether this skepticism is founded is uncertain as virtually all studies on drug
distribution and transport kinetics have been done on previously intact blood vessels in healthy
animals [22, 23]. Since drug administration builds its efficacy on the response of the disease
state the potential inferences from examination of drug transport in healthy and not diseased
tissues might be limited. For example, the variations in the lipid content of atherosclerotic
plaque may alter the drug distribution pattern after directed vascular delivery and change the
efficacy [20]. At the very least, the increased tissue beneath endovascular stents placed in
anatomically large or hyperplastic arteries increases the time and mass through which drugs must
diffuse, potentially leading to delayed and diluted pharmacological response [23]. The
mechanism of drug transport, the relative importance between the diffusive and convective
forces, may also change as the diffusive resistance increases with vessel thickness (convection
may come to play a more significant role). Therefore, studies of drug interaction with healthy
tissues can only be useful to a certain extent, and need to be followed by studies in diseased
tissues.
This view is further supported by disparity between early and late results of DES that could not
have been anticipated from animal models. The early Sirius[26] clinical trial showed that 93.4%
of patients were free from target lesion revascularization (TLR) 2yrs following the initial
procedure. This was contrasted to 80.4% of patients who had received bare metal stents.
However, the Basket Late Trial (presented at the ACC 2006, [27]) investigated the incidence of
late clinical events with respect to restenosis. The results showed a non-statistically significant
increase of thrombotic events in DES when compared to BMS (2.6 vs. 1.3% respectively), and a
statistically significant increase in combined fatal and non-fatal MI in DES when compared to
BMS (4.9 vs. 1.3%, respectively). Further, Aoki et al. [28] showed in 2005 that plaque volume
and hypoechogenicity decrease (indicating normal tissue formation) only 2-4yrs following the
DES placement. This implies that DES are potent modulators of vascular repair, and delay
vessel healing beyond the time line previously anticipated. This delayed healing have not been
observed in preclinical studies, where healthy models are used, emphasizing the impact of
atherosclerosis on the healing process and the importance of using diseased models for device
design and evaluation.
This body of work was designed to investigate mechanisms of drug deposition, distribution and
transport kinetics across healthy and atherosclerotic arteries. The results will enable us to
understand more fully the potential of local cardiovascular drug delivery within the system in
which it is to act. In addition, they will further guide establishing valuable and meaningful
disease models for design and evaluation of endovascular devices.
Research Significance
This work examines the transport of several compounds (dextran, paclitaxel, rapamycin,
everolimus) with different physicochemical properties (hydrophobicity, binding properties)
across atherosclerotic-like arteries (hyperplastic, inflammatory, and lipid enriched), where the
disease state was defined in terms of arterial ultrastructure (lipid, binding protein, collagen, and
elastin content). I showed that:
1. uptake and elution kinetics, as well as equilibrium deposition and distribution, are guided
by drug physicochemical and binding properties,
2. altered stent release kinetics affected drug deposition,
3. disease changes the arterial ultrastructure, which in turn affects drug deposition and
distribution across the arterial wall.
Hypothesis
The underlying hypothesis that drove my work was that pathology changes the state of an artery.
That change alters tissue properties, which in turn affect drug transport (deposition, distribution,
binding, and kinetics) across an arterial wall and atherosclerotic lesions. The resulting drug
deposition and distribution within the target arterial wall will determine the efficacy and safety of






Figure 1 A Diagram of the Wall of Human Aorta
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Figure 2 Pathways in Evolution and Progression of Human Atherosclerotic Lesions
From type I to type IV, changes in lesion morphology occur primarily because of increasing
accumulation of lipid. The loop between types V and VI illustrates how lesions increase in
thickness when thrombotic deposits form on the surfaces.
Figure 3 Proposed Role of LDL Oxidation in the Initiation of Fatty Streak Lesions
LDL crosses the endothelium in a concentration-dependent manner and can become trapped in
the extracellular matrix (1). The subendothelium is an oxidizing environment, and if the LDL
remains trapped for a sufficiently long period of time, it undergoes oxidative changes (2). Mildly
oxidized forms of LDL contain biologically active phospholipid oxidation products that affect
the pattern of gene expression in endothelial cells (ECs), leading to, among other things, changes
in the expression of monocyte binding molecules (designated X-CAM), monocyte
chemoattractant protein (MCP-1), and macrophage colony stimulating factors (CSFs) (3). These
factors in turn promote the recruitment of monocytes (4) and drive their phenotypic
differentiation to macrophages (5). Further oxidation leads to alterations in apolipoprotein B
such that LDL particles are recognized and internalized by macrophages (6), progenitors of the
lipid-laden foamn cells. Marked increases in lipid and cholesterol oxidation products render the
LDL particles cytotoxic, leading to further endothelial injury (7) and favoring further entry of
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CHAPTER 2: Pharmacokinetics in the Healthy Arterial Wall - In
Vitro Study
2.1 Background, Hypothesis, and Specific Aims
Background
The success of drug-eluting stents is predicated to as great a degree upon the extent of drug
deposition and distribution through the arterial wall as virtually any other factor (1-5). The
biological effects of a candidate drug are essential, but, ultimately, tissue residence time will
determine effect and toxicity (6, 7). Fueled by clinical relevance (8-11), a number of studies
have been carried out to detect, model, and predict the distribution of drugs within arterial
segments beneath, adjacent to, and distant from stents (12-15). Drugs that are retained within the
blood vessel are far more effective than those that are not. Heparin is a perfect example of a
compound whose ubiquitous biological potential is lost by virtue of its physicochemical
properties. Heparin regulates virtually every aspect of the vascular response to injury (16). Yet
heparin is so soluble and diffusible that it simply cannot stay in the artery for more than a few
minutes after release and has no effect on intimal hyperplasia when eluted from a stent (4, 17,
18).
Paclitaxel, in contradistinction, is a far smaller compound, with fewer effects specific to vascular
biology, but paclitaxel is so hydrophobic and insoluble that it binds tenaciously to tissue protein
elements and remains beneath stent struts long after release (13). The clinical efficacy of
paclitaxel at reducing restenosis rates following elution from stents appears incontrovertible (8,
11). In addition to its hydrophobic, nonspecific binding behavior, paclitaxel also binds to its
protein target, polymerized microtubules (19), with nanomolar specificity. Analogously,
rapamycin, also successful after local vascular delivery (10), acts on a specific target through a
series of events that requires binding to the specific binding proteins FKBP12 (FK506 binding
protein 12) and FRAP (FKBP12-rapamycin-associated protein) (20, 21). The distribution of
tissue-binding proteins is not uniform in space or time. For example, FKBP12 is found most
abundantly in vascular smooth muscle cells at a concentration of -10-5 M (22). FKBP12 is up-
regulated in neuronal systems with injury (23) and likely after arterial injury as well.
Microtubules have a similar cellular concentration of =10-5 M (24). The nonuniform distribution
of paclitaxel previously observed in the arterial wall may reflect an inhomogeneous distribution
(13) of polymerized microtubules or carrier proteins (25).
Although regulated at a coarse level by transport forces and lipid avidity, the distribution of
paclitaxel and rapamycin is also regulated at a fine level by the distribution and availability of
their protein targets, a level of control not present for drugs such as heparin that are rapidly
cleared from arterial tissue. With a more complete understanding of the role of specific binding
in arterial drug distribution, stent design, drug composition, and release formulation can be better
optimized.
Hypothesis
We hypothesized that drug physicochemical properties will affect their tissue pharmacokinetics.
More specifically, hydrophobic drugs, as opposed to hydrophilic drugs, will have increased
deposition and retention levels, and longer equilibration times. Further, the arterial wall
distribution and local pharmacological effects of compounds such as paclitaxel and rapamycin
will be influenced by tissue-specific binding proteins, above and beyond the influence of general
hydrophobic interactions alone.
Specific Aims
To test the above hypothesis we examined tissue uptake and elution kinetics, equilibrium
deposition levels, and arterial wall distribution profiles for a model hydrophilic drug, dextran,
and two model hydrophobic drugs, paclitaxel and rapamycin.
2.2 Materials & Methods
Equilibrium Drug Deposition as a Function of Bulk Concentration.
Samples of calf carotid artery were placed in drug solution (radiolabeled paclitaxel in PBS, or a
mixture of radiolabeled and unlabeled paclitaxel) at room temperature for 48hrs. Following
incubation, tissue samples were digested, liquid scintillation cocktail was added, and drug
quantity determined by LSC.
Arterial Loading and Elution. We defined the tissue pharmacokinetic profiles of dextran
(10,000 Da), paclitaxel (853.9 Da), and rapamycin (914.2 Da) in calf carotid arterial wall
segments. Calf internal carotid arteries were harvested and transported in PBS with physiological
calcium and magnesium [PBS++/0.01 mol/liter CaC12/0.01 mol/liter MgC12 (Sigma)] at 40C.
Arteries were cleaned of excess fascia, opened longitudinally, cut into segments (400-600 mg),
and placed in centrifuge tubes with 1.0 ml of [3H]dextran (10-6 M), [3H]paclitaxel (10-6 M), or
[14C]rapamycin (10-6 M). All bulk solutions were made fresh immediately before
experimentation, and the same initial bulk concentrations were used for both loading and elution
experiments.
For loading experiments, segments were removed in triplicate at indicated time points, briefly
washed in PBS++, and blot-dried before being dissolved in Solvable (Packard-Canberra). Liquid
scintillation mixture (6 ml) was added to dissolved samples before counting with liquid
scintillation spectroscopy (2500 TR Liquid Scintillation Analyzer, Packard-Canberra). For
elution experiments, segments were allowed to equilibrate for 60 h and were then placed in 50
ml of PBS++ for the indicated time periods before being processed in triplicate as indicated with
the loading experiments.
Drug Tissue Uptake Capacity (TUC) and Distribution.
We defined the bulk differential capacities of the arterial wall for dextran, paclitaxel, and
rapamycin at equilibrium. Arterial segments were weighed before being placed in drug bath
solutions. Segments were allowed to equilibrate for 60 h and were then processed for liquid
scintillation counting. The drug concentration of each tissue sample was normalized by tissue
mass and then by drug concentration in the bulk fluid during equilibrium incubation to determine
the uptake capacity. As indicated, tissue was incubated with (i) labeled drug alone to determine
TBC; (ii)drug and supersaturated levels of the same unlabeled drug to demonstrate that specific
and nonspecific tissue-binding sites can be displaced; and (iii) supersaturated levels of the other
nonlabeled hydrophobic drug (i.e., labeled rapamycin was mixed with cold paclitaxel, and vice
versa) to displace only nonspecific binding.
Equilibrated transmural drug distribution in the artery was measured through en face
cryosectioning. Arterial segments were incubated in the drug bath for 60 h, and then laid flat
and snap-frozen in a plastic encasement with Tissue-Tek OCT compound (Sakura Finetechnical,
Tokyo). Samples were stored in a -800 C freezer until they were sectioned parallel to the intima
with a refrigerated microtome, the Cryotome SME (Shandon, Pittsburgh) (12, 26, 27). Upon
sectioning, the segment length and width were measured with a caliper. Sections 0.040 mm thick
were cut parallel to the intima, and the drug content of each sample was determined by liquid
scintillation spectroscopy. Tissue drug concentration (cT) at each transmural location was
calculated as the mass of drug normalized by the measured tissue area and slice thickness. Tissue
drug concentration was then normalized by the bulk fluid drug concentration during equilibrium
incubation (cbulk) to determine the uptake capacity (k) at each transmural location (x).
2.3 Results
2.3.1 Equilibrium Drug Deposition as a Function of Bulk Concentration.
In preliminary experiments, it was determined that equilibrium drug deposition in calf carotid or
rabbit abdominal aorta samples is reached in 24-36 hours. Next, we were interested to know if
this deposition is dependant upon the drug concentration in the bulk or surrounding solution.
The total tissue uptake capacity (TUC) of paclitaxel increased twofold as the bulk concentration
increased from 10-9M to 10-8M. As the bulk concentration was increased further to 10-5M
paclitaxel uptake capacity continually decreased (Figure 5).
2.3.2 Tissue-Uptake Kinetics.
Arterial samples were incubated in [3H]dextran (10-6 M), [3H]paclitaxel (10-6 M), or
[14C]rapamycin (10-6 M) and harvested in triplicate over a period of 72 h. Loading data were
normalized to an average peak value at 72 h (Figure 6). Whereas the hydrophilic dextran reached
80% of equilibrium value within several hours, paclitaxel and rapamycin took nearly 1 day to
achieve the same level. The loading profiles for these two hydrophobic compounds are
indistinguishable and approach steady state only after 60 h.
2.3.3 Tissue-Elution Kinetics.
Arterial samples were pre-equilibrated in [3H]dextran (10-6 M), [3H]paclitaxel (10-6 M), or
[14C]rapamycin (10-6 M) for 60 h and then placed in an elution sink of 50 ml of PBS++.
Samples were processed in triplicate over the following 60 h, and data were plotted as
percentages of the pre-elution load value (Figure 7). Dextran elutes most rapidly, losing 90% of
its equilibrated load within 2 h and reaching a steady state of =10% of original material in <5 h.
The hydrophobic drugs take =1 day to reach an elution steady-state value. At 48 h, arterial
segments loaded with rapamycin retain =60% of their initial load, and those loaded with
paclitaxel, =35%.
2.3.4 Total Uptake Capacity.
TUC was defined as the tissue concentration (cT) at equilibrium normalized by the bulk
concentration at equilibrium (cbulk). Arterial segments were incubated in the drug for 60 h to
allow for equilibration. Upon equilibration, bulk solutions were sampled, and tissue samples
were processed for liquid scintillation counting. Variation in initial bulk concentrations over an
order of magnitude did not affect TBC. Dextran has little uptake capacity in arterial tissue with a
coefficient of =0.60. Because this value is similar to its physically accessible volume fraction in
arterial tissue (17), dextran may not leave the extracellular space. The paclitaxel and rapamycin
binding coefficients are not statistically different (P > 0.05) by the two-tailed Student t test and
are significantly greater than 1, indicating that nonspecific and/or specific binding interactions
are sequestering these drugs in the tissue (Figure 8).
To assay for the binding specificity, experiments were conducted with mixtures of labeled and
nonlabeled drug (Figure 9). Molar excess of unlabeled paclitaxel or rapamycin displaced the
binding of the corresponding labeled drug to <5% of control value. At this level the TBC value
fell to nearly 1, indicating displacement of specific and nonspecific binding. When the cold drug
was switched, the TBC decreased to =35% of control for paclitaxel and =50% for rapamycin,
suggesting that these compounds were now displacing the unrelated labeled drug, although
displacement occurred only from nonspecific sites, leaving specific binding intact. By the two-
tailed Student t test, the paclitaxel and rapamycin specific retention fractions are statistically
different (P < 0.05).
2.3.5 Transmural Drug Distribution.
Arterial samples were incubated in [3H]dextran, [3H]paclitaxel, or [14C]rapamycin for 60 h and
then snap-frozen for en face sectioning (Figure 10). Previous work with paclitaxel in BSA
showed that TBC was maximal in the intima and declined precipitously within the most intimal
regions of the arterial media, to less than half the intimal level. At the outer edge of the media,
the paclitaxel uptake capacity increased gradually and peaked within the adventitia before falling
off to unity (13). These data have been recapitulated, but without BSA, for direct comparison
with dextran and rapamycin. In this case, paclitaxel shows a very similar medial profile to the
BSA case, but rises sharply in the adventitia, suggesting that BSA provides a nonspecific binding
sink for adventitial binding. Rapamycin shows a uniform transmural distribution, in stark
contrast to the nonuniform distribution of paclitaxel. Dextran again shows little uptake capacity
throughout the artery.
2.4 Discussion
Local drug delivery has great theoretical and practical appeal for vascular diseases (28, 29). One
important surprise is that biological potency is not the sole determinant of biological effect.
Drug-specific physicochemical properties determine, to a great degree, whether concentrations
sufficient for therapeutic activity can be sustained. Drugs that bind to tissue elements, for
example, are retained within tissue and have dramatic clinical effects; nonbinding hydrophilic
drugs are rapidly cleared and ineffective against restenosis. Our data suggest that specific
binding also plays a critical role in determining drug distribution. Whereas paclitaxel distributes
heterogeneously through arterial tissue, rapamycin distributes more uniformly through the media
and adventitia. In addition, the tissue binding and diffusion results suggest that binding site
availability and distribution regulate the fine structure of drug deposition beyond the coarse
structure imposed by transport forces and lipid avidity. Ultimately, local tissue ultrastructure and
the concentrations they enforce on the artery at a microscopic scale, together with specific and
nonspecific binding site distribution, become critical considerations in the optimization of
vascular drug delivery.
Specific and Nonspecific Binding Determine TBC. Compounds must bind to proteins,
intracellular or extracellular, to have a biological effect. This binding can take two forms:
nonspecific interactions, such as those influenced by charge or water affinity, and specific
binding idiosyncratic to the individual drug. Paclitaxel and rapamycin both can bind
nonspecifically to serum proteins and hydrophobic tissue microenvironments. Paclitaxel
demonstrates nanomolar specificity to polymerized microtubules, whereas rapamycin shows
similar specific binding properties to FKBP12, a ryanodine-receptor-associated protein. Dextran,
by virtue of its extreme hydrophilicity, exhibited neither type of binding and, accordingly, its
TBC was <1; its potential tissue level can never exceed the concentration in the bathing solution.
In contrast, paclitaxel and rapamycin were deposited in the blood vessel at concentrations 30- to
40-fold higher than that in surrounding bulk solutions. Thus, tissue concentrations of paclitaxel
and rapamycin can exceed the applied concentration several fold, establishing an effective
volume of distribution within arteries larger than anticipated from surrounding solution
concentration.
Because both microtubules and FKBP, which specifically bind paclitaxel and rapamycin,
respectively, reside in calf internal carotid segments at -10-5 M (24), offering a large specific
drug sink, we investigated the specificity and potential of tissue binding by using a competitive
binding tissue assay. Both specific and nonspecific binding contributions were observed. When
cold rapamycin was substituted for a high concentration molar excess of paclitaxel in the labeled
paclitaxel system, the fractional TBC was nearly 35%, indicating that approximately one-third of
the TBC was from specific binding. Comparably, when the same procedures were carried out
with labeled rapamycin and excess cold paclitaxel, the fractional TBC was 50%, with near equal
contributions from specific and nonspecific binding events. Taking into account specific,
nonspecific, and general binding a summary diagram can be made to demonstrate types of
interactions that hydrophobic drugs can be involved in (Figure 11).
Tissue Pharmacokinetics of Hydrophilic and Hydrophobic Compounds. It is expected that
paclitaxel and rapamycin will have similar transport properties, given that both compounds have
solubilities of =6 gLg/ml, molecular masses of <1 kDa, and nanomolar binding constants to their
specific protein targets. Indeed, the compounds act quite similar when compared with dextran.
Whereas only several hours are required for dextran to reach a steady-state tissue concentration
that never exceeds the surrounding media levels, paclitaxel and rapamycin take four to six times
longer to reach a steady state. Kinetics, not concentration, accounts for this effect, as the time to
reach steady state was independent of the concentration of the same drug applied over a broad
range. Although the net binding of paclitaxel and rapamycin were nearly identical, their
distribution and tissue elution after binding and uptake were not. At steady state the artery
retained only 10% of the applied hydrophilic dextran. Paclitaxel retention was 3.5-fold that of
dextran, and rapamycin levels were almost twice those of paclitaxel. These differences in tissue
retention closely parallel the percentages attributed to specific binding (Figure 9), and it is clear
that both hydrophobic compounds are retained to a much greater extent than dextran. Moreover,
at steady-state loading, whereas paclitaxel remained in the subintimal space and partitioned
significantly in the adventitia, rapamycin was evenly distributed throughout the arterial wall
(Figure 10).
Movement of a molecule through a composite structure, such as a blood vessel wall, is driven by
a range of forces and phenomena. The influence of effective molecular radius can dominate
when all other :factors are equal but may recede in importance when other factors are present. For
instance, despite being nearly 20 times smaller than dextran, paclitaxel and rapamycin diffuse
more slowly in both the transmural and planar directions. This difference may be attributed to the
hydrophobicity of the compounds or possibly to the role of binding. Whereas dextran has few
binding sites, paclitaxel and rapamycin will repeatedly bind to and dissociate from their
respective specific and nonspecific targets as they diffuse through tissue, in effect slowing the
leading edge of the diffusion front. We have previously shown that albumin and dextrans diffuse
at least an order of magnitude faster in the planar direction than they do in the transmural
direction (3). For paclitaxel and rapamycin, the planar diffusivity exceeded transmural diffusivity
by at least two orders of magnitude, although both drugs' diffusivities were two orders of
magnitude smaller than those of dextran. These phenomena are likely governed by similar forces
for all three drugs, despite vastly different lipid avidities. The transport of hydrophilic
compounds is enhanced in aqueous regimes of the vessel wall but retarded by hydrophobic
elastin layers. For hydrophobic compounds, these layers act in a reverse fashion; the movement
of paclitaxel and rapamycin is likely impeded by the more water-rich regions of the blood vessel
wall and aided by lipid pools or even the protein-studded elastin lamina. In both cases, however,
whereas individual layers might be isotropic, the greater composite of alternating layers of the
arterial wall provide for planar diffusion that far exceeds transmural flux (3).
As the number of available drug-eluting devices increases, distinction and choice may reside not
only in ease of use but also in the physicochemical functionality of the drug-stent unit. Local
drug distribution is modulated by transport and lipid avidity at a coarse level, but for clinically
relevant compounds such as rapamycin and paclitaxel, it is also modulated by the distribution of
the compounds' specific binding sites. Arterial ultrastructure also influences transport, because
alternating tissue layers of varying permeability result in anisotropic transport for both
hydrophobic and hydrophilic drugs. Design and evaluation of a drug-eluting device thus requires
a unified understanding of the drug, its physicochemical characteristics, and its specific and
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Figure 5 Equilibrium tissue uptake capacity of Paclitaxel as a function of bulk concentration
(in PBS and room temperature, calf internal carotid artery samples; mixtures of radiolabeled and











Figure 6 Tissue uptake profiles ofradiolabeled dextran (*), paclitaxel (0), and rapamycin (0)
in calf internal carotid artery samples. Hydrophobic paclitaxel and rapamycin reach steady state









Figure 7 Tissue elution profiles of radiolabeled dextran (*), paclitaxel (o), and rapamycin (0)
from calf internal carotid artery samples. Hydrophobic paclitaxel and rapamycin reach an











Figure 8 Tissue uptake capacity of radiolabeled dextran, rapamycin, and paclitaxel









Figure 9 Fractional tissue uptake capacity of labeled paclitaxel (m) and rapamycin (0)
when in the presence of excess unlabeled drug, relative to the capacity of labeled drug alone,
after 60 hours of incubation. (1) Rx: 10-6M labeled drug with 10-3M of the same unlabeled drug.
(2) Rx': 10-6M labeled paclitaxel with 10-3M unlabeled rapamycin, and 10-6M labeled rapamycin



















0.4 0.5 0.6 0.7
Depth from Lumen (mm)
Figure 10 Transmural equilibrium distribution
of labeled dextran (,), paclitaxel (o), and rapamycin (0) in 0.040 mm thick calf internal carotid
samples. Compared to hydrophilic dextran, the profiles ofhydrophobic drugs demonstrate
nonuniform distribution across the arterial wall as well as higher deposition levels.
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Figure 11 Summary of drug-tissue interactions:
Hydrophilic drugs deposit into and clear from the tissue too fast to exert a pharmacologic effect.
Hydrophobic drugs bind long enough for an effect to take place. Within the extracellular
compartment, a given hydrophobic drug (ex, paclitaxel) will bind to non-specific sites that are
also accessible to other drugs. It will also bind to specific sites that are accessible to that drug
alone (ex, a specific site on elastin). Intracellularly, a drug can bind to a general site from which
it can be displaced by other drugs (ex, a lipid droplet) or to a specific site from which it can't be
displaced by other drugs (ex, microtubules).
I
2.5 References
1. Hwang, C. W., Wu, D. & Edelman, E. R. (2001) J. Am. Coll. Cardiol. 37:, Suppl. A, 1A-2A.
2. Hwang, C. W., Wu, D. & Edelman, E. R. (2001) Circulation 104:, 600-605.
3. Hwang, C. W. & Edelman, E. R. (2002) Circ. Res. 90:, 826-832.
4. Lovich, M. A.., Brown, L. & Edelman, E. R. (1997) J. Am. Coll. Cardiol. 29:, 1645-1650.
5. Lovich, M. A. & Edelman, E. R. (1995) Circ. Res. 77:, 1143-1150.
6. Edelman, E. R. & Lovich, M. (1998) Nat. Biotechnol. 16:, 136-137.
7. Wan, W. K., Lovich, M. A., Hwang, C. W. & Edelman, E. R. (1999) J. Pharm. Sci. 88:, 822-829.
8. Grube, E., Silber, S., Hauptmann, K. E., Mueller, R., Buellesfeld, L., Gerckens, U. & Russell, M. E.
(2003) Circulation 107:, 38-42.
9. Marks, A. R. (2003) N. Engl. J. Med. 349:, 1307-1309.
10. Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo,
R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) N. Engl. J. Med. 349:, 1315-1323.
11. Buellesfeld, L., Gerckens, U., Muller, R. & Grube, E. (2003) Z. Kardiol. 92:, 825-832.
12. Bratzler, R. L., Chisolm, G. M., Colton, C. K., Smith, K. A., Zilversmit, D. B. & Lees, R. S. (1977)
Circ. Res. 40:, 182-190.
13. Creel, C. J., Lovich, M. A. & Edelman, E. R. (2000) Circ. Res. 86:, 879-884.
14. Edelman, E. R., Nathan, A., Katada, M., Gates, J. & Karnovsky, M. J. (2000) Biomaterials 21:, 2279-
2286.
15. Edelman, E. R., Nugent, M. A. & Karnovsky, M. J. (1993) Proc. Natl. Acad. Sci. USA 90:, 1513-
1517.
16. Nugent, M. A., Karnovsky, M. J. & Edelman, E. R. (1993) Circ. Res. 73:, 1051-1060.
17. Lovich, M. A. & Edelman, E. R. (1996) Biophys. J. 70:, 1553-1559.
18.Lovich, M. A., Philbrook, M., Sawyer, S., Weselcouch, E. & Edelman, E. R. (1998) Am. J. Physiol.
275:, H2236-H2242.
19. Manfredi, J. J., Parness, J. & Horwitz, S. B. (1982) J. Cell Biol. 94:, 688-696.
20. Wandless, T. J., Michnick, S. W., Rosen, M. K., Karplus, M. & Schreiber, S. L. (1991) J. Am. Chem.
Soc. 113:, 2339-2341.
21. Choi, J. W., Chen, J., Schreiber, S. L. & Clardy, J. (1996) Science 273:, 239-242.
22. Siekierka, J. J., Hung, S. H., Poe, M., Lin, C. S. & Sigal, N. H. (1989) Nature 341:, 755-757.
23. Sezen, S. F., Blackshaw, S., Steiner, J. P. & Burnett, A. L. (2002) Int. J. Impot. Res. 14:, 506-512.
24. Hiller, G. & Weber, K. (1978) Cell 14:, 795-804.
25. Lovich, M. A., Creel, C., Hong, K., Hwang, C. W. & Edelman, E. R. (2001) J. Pharm. Sci. 90:, 1324-
1335.
26. Ramirez, C. A., Colton, C. K., Smith, K. A., Stemerman, M. B. & Lees, R. S. (1984) Arteriosclerosis
(Dallas) 4:, 283-291.
27. Penn, M. S., Koelle, M. R., Schwartz, S. M. & Chisolm, G. M. (1990) Circ. Res. 67:, 11-22.
28. Schwartz, R. S. & Henry, T. D. (2002) Rev. Cardiovasc. Med. 3:, Suppl. 5, S4-S9.
29. Carter, A. J. (2002) Catheter. Cardiovasc. Interv. 57:, 69-71.
CHAPTER 3: Pharmacokinetics in the Atherosclerotic Arterial
Wall - In Vitro Study
3.1 Background, Hypothesis, and Specific Aims
Background
The efficacy and safety of drugs eluted from endovascular implants are determined by drug
deposition, retention and distribution within the target arterial wall. Arterial ultrastructure can
dramatically alter the interaction between the drug and the arterial wall, leading to altered
efficacy and safety of drugs delivered to the vascular site. We sought to examine the
ultrastructural changes that occur in the atherosclerotic arterial tissue and how these changes
impact the deposition and distribution of three model drugs, Paclitaxel, Rapamycin, and
Everolimus.
Hypothesis
The formulated hypothesis was that the alterations in tissue architecture that accompany the
disease process of atherosclerosis alter drug deposition and localization, ultimately affecting the
safety and efficacy of Drug Eluting Stents.
Specific Aims
To test the hypothesis we set forth the following specific aims:
1. Examine drug deposition and localization as well as ultrastructural changes in a diseased
state, and
2. Correlate changes in drug deposition and localization with changes in arterial ultrastructure
precipitated by disease.
In particular we induced varied degree of vascular injury including those designed to alter
extracellular matrix and basement membrane components, smooth muscle cell proliferation and
the amount of local lipid.
3.2 Materials & Methods
3.2.1 Model Drugs
Three model drugs were used for studies in diseased arteries, Paclitaxel, Rapamycin (Sirolimus),
and Everolimus (a Sirolimus analog). These drugs were chosen because of their clinical
relevance. At the time when these studies were commenced, Paclitaxel and Sirolimus eluting
stents were already in clinical use (approved in the US in 2003 and 2004, respectively, and about
a year prior in Europe), and Everolimus eluting stents were in the clinical testing stage.
H3-labeled Paclitaxel was obtained from Vitrax (catalog no. VT-180). C14- or H3-labeled
Everolimus was supplied by the Guidant Corporation (Santa Monica, CA). C14-labeled
Rapamycin was supplied by the Cordis division of Johnson&Johnson.
3.2.2 Arterial Models of Atherosclerosis
Tissues were obtained from four different and related arterial beds with variable degrees of
atherosclerosis, including arteries from: human autopsy specimen, the rabbit iliac artery and
aorta one month after altered diet, and the rabbit abdominal aorta after a more prolonged dietary
alteration.
The Human atherosclerotic arteries
Sections of the human abdominal aorta were obtained post-autopsy from the Pathology
Department of the Brigham and Women's Hospital (Boston, MA) under COUHES protocol.
Specimen from 4 subjects were used in these studies. All specimen were obtained within 24hrs
post-mortem and were atherosclerotic in nature containing visible lipid infiltrates, fatty lesions,
or areas of hardness on gross examination.
The Rabbit 1-month Abdominal-Aorta model
Mail New Zealand White Rabbits, weighing 3.0-3.5kg, approximately 3months old, were either
fed normal or high cholesterol/high fat diet for 4 weeks, injured at 2 weeks, and sacrificed at 4
weeks. The balloon size was the same as for the iliac model (3F Fogarty Arterial Embolectomy
catheter, Edwards Lifescience, catalog no. 120403F). This size however was deemed
insufficient for the abdominal aorta, as it produced lesions that were not uniform around the
perimeter and a different balloon (12TLW403F) was used in a subsequent experiment (the 5-
month model). The iliac arteries and abdominal aorta were harvested fresh, without pressure or
perfusion.
The advantages of this model were (1) relatively short time period to obtain the model, which is
4 weeks from the time animals are started on the special diet, (2) relative ease (compared to pigs,
for example) in handling these animals, and (3) arterial size, which is similar to that of the
human coronary arteries, and thus conductive to stenting by generally available stents. On a
downside, this model was more labor-intensive than the human model and required arterial
balloon injury.
The Rabbit 5-month Abdominal Aorta model
Animals were kept on either normal or high cholesterol/high fat diet for one month. Balloon
injury of the abdominal aorta was performed at 2 weeks. To make sure sufficient lesions
develop a new type of catheter was used for this model, a 3F Fogarty Thru-Lumen Catheter
(Edwards Lifesci., cat.no. 12TLW403F). Aside, a 4F thru-lumen catheter was originally tried,
but was too big (to pass through the vasculature). Following one month, all animals were
maintained on normal diet for approximately 4 months. At the end of 4 months (5 months total)
one animal from each of the two groups was sacrificed and used for drug uptake or tissue
ultrastructure studies.
3.2.3 Drug Detection Techniques
Model drugs were used for several experiments:
1. tissue incubation in solutions of radiolabeled drugs to determine total tissue drug uptake,
2. transmural cryosectioning of samples, previously incubated in a radiolabeled drug
solution, to determine drug transmural profile, and
3. tissue incubations in a solution of fluorescently labeled drug (FITC-Paclitaxel, Figure 12)
to determine the drug arterial profile and correlate it with profiles of structural elements, like
lipid, binding protein, collagen, or elastin.
Detailed methods for these experiments are given in the Appendix. Methods 1 and 2 had been
previously used in our laboratory, and method 3 was a novel technique developed for this body
of work.
3.2.4 Ultrastructure Determination Techniques
Cholesterol content in arterial tissue was assayed using standard homogenation and cholesterol
extraction technique and cholesterol quantification by ThermoElectron. A detailed protocol is
included in the Appendix.
Histology Staining was done using Oil-Red-O stain for Lipids, Verhoeff stain for Elastin,
Picrosirius Stain for Collagen, and a-Actin stain for Smoot muscle cells. These stains were done
by the Histology unit of the Edelman Laboratory, and the protocols can be obtained from Philip
Seifert (Oil-Red-O staining was in several cases done by Neda Vukmirovic and is included in the
Appendix). The protocols that were developed for novel immunostains b-Tubulin and FKBP-12
in paraffin sections, are included in the Appendix.
Figure 12 Chemical Structure of FITC-Paclitaxel conjugate
Tubulin Tracker Green (Oregon Green 488 Paclitaxel, Bisacetate)
Paclitaxel (shown for comparison)
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3.3 Results
3.3.1 FITC-Paclitaxel Tracking Techniques
FITC-Paclitaxel conjugate (or Tubulin Tracker) technique allows us to visualize the drug in
histology cross-sections and correlate it with ultrastructure visualized also in histology sections.
The technique used a FITC labeled paclitaxel conjugate, Oregon Green 488 Bisacetate or
Tubulin Tracker (Figure 12). As with some FITC labeled compounds tissue autofluorescence is
significant and interferes with drug labeled compound [2] autofluorescence was tested in this
case. Tissue without any drug or saturated by (non-labeled) Paclitaxel showed no
autofluorescence, when viewed using the same exposure time and under the same FITC filter as
the FITC-labeled drug sample (Figure 13a). FITC-paclitaxel incubated tissue showed distinct
green color to indicate the location of the drug (Figure 13b). When the tissue was incubated in
(non-labeled) Paclitaxel, and then with FITC-labeled Paclitaxel there was no fluorescent drug in
the tissue (Figure 13c) indicating that the binding properties of a non-labeled and the labeled
drug are comparable and that there is no free label in the tissue.
3.3.2 Human tissue
Sample of human abdominal aorta obtained from autopsy cases within 24hrs post-mortem are the
most relevant to a clinical situation and showed advanced stages of disease, not seen in animal
models. Advanced stages of disease are more likely to emphasize differences in drug deposition
and distribution that exist between diseased and healthy arteries, as well as dependency of drug
localization on structural changes of disease.
There were two methods in which drug deposition was assessed in the human abdominal aorta.
In the first method, samples from the whole artery (which included neointima, media, and
adventitia) were incubated in a drug solution until equilibrium. Whole-artery samples were
taken from two morphologically distinct areas, one that was yellow on gross-examination and
supple on palpation (termed "early lesion"), and the other which was off-white in appearance and
harder on palpation (termed "late lesion", Figure 15). Deposition of paclitaxel and everolimus
was lower in "late lesion" samples than in "early lesion" samples (Figure 16). The difference
was statistically significant (p < 0.05) in both cases. Also, paclitaxel deposition was higher that
that of everolimus for both cases, potentially because paclitaxel physicochemical properties
and/or binding characteristics relate to lesion ultrastructure in such a way to increase drug
deposition.
The other method in which deposition was assessed was by separating the artery in 3 constituent
layers (neointima, media, and adventitia, Figure 17) and incubating each layer separately in the
drug solution. It is worth noting that arteries with an early stage of disease cannot be separated
into its constituent layers. However, some arteries with an advanced stage of disease separate
readily into 3 layers or compartments (Figure 18a), while others don't have distinct planes of
separation and either tear or separate into more than three layers (Figure 18b). Only arteries that
separated readily were used for individual-layer drug incubation experiment. Histology was also
performed on each layer to confirm that the separation had occurred along the internal or
external elastic lamina.
Samples from each layer were assayed for cholesterol content and the data were plotted as drug
uptake vs. cholesterol content of each layer (Figure 19). Deposition of all drugs was inversely
proportional to cholesterol content, with media having the least cholesterol and the highest
amount of drug, and the neointima having the most cholesterol and the least amount of drug.
The adventitia was in-between in terms of cholesterol content and the drug uptake. From three
drugs, paclitaxel showed to be the most sensitive to cholesterol content and showed the greatest
decrease in deposition with increased cholesterol.
3.3.3 Rabbit Abdominal Aorta Tissue: 1 month of high fat diet
Because of a need to control for disease and an unpredictable and at times limited supply of
human specimen a rabbit model of atherosclerosis was chosen for continuation of the studies.
We employed two groups of rabbits. Both groups underwent balloon injury of the abdominal
aorta 2-weeks after the start of the experiment, and only one was given special diet from time
zero to the conclusion of the experiment (4 weeks later). Both groups developed a thin
neointima (Figure 20), while only the second group had arterial lipid infiltrates (shown in
red/purple, Figure 20b). When drug uptake in these arteries was assessed by incubating arteries
in radiolabeled drug solutions until equilibrium, control arteries showed a slightly greater (and
non-significant) uptake than diseased arteries (Figure 21). In addition, paclitaxel and everolimus
levels in both types of arteries were about the same.
When drug transmural profile was assessed via cryosectioning two patterns emerged for
Paclitaxel (Figure 22). All arteries had a bell-curve shaped profile. Disease altered the pattern
for paclitaxel deposition but not everolimus (Figure 23). Diseased arteries has a net lower peak
amount of drug but deeper penetration. We focused on paclitaxel to pursue studies of drug
deposition dependence on ultrastructure as (1) deposition of paclitaxel showed more sensitive to
changes in disease than everolimus, (2) paclitaxel is readily available both as a radiolabeled
compound and as a fluorescently labeled compound (the latter being of crucial importance for
correlations with ultrastructure, and (3) paclitaxel shelf life and stability was greater than that of
everolimus.
To explain deposition patterns of paclitaxel we examined four ultrastructural elements whose
presence may change with disease: b-tubulin, lipid, collagen, and elastin. Beta-tubulin is a
constituent of every cell (smooth muscle cell or macrophage) and is a paclitaxel specific binding
protein. It can also be indicative of a cell number. Lipid is present as lipid infiltrates, and
collagen and elastin ratio is known to change with disease [1].
3.3.4 The Rabbit Iliac Artery: 1 month of high fat diet
This model was used to test the fate or binding proteins, b-tubulin in case of paclitaxel, and
FKBP-12 in case of everolimus, with disease. This model was chosen because it was known to
produce a neointima and rich lipid infiltrates (Figure 25). The control samples in this study were
the native iliac artery. Diseased samples were the 1-month single injury model on high
cholesterol (2%) diet (injury at 2 weeks and sacrifice at 4 weeks). Using a novel staining
technique for b-Tubulin and FKBP-12 we showed that there is a significant upregulation of b-
Tubulin with disease, (Figure 24b) and a slight upregulation of FKBP-12 (Figure 24d). The
upregulation is in both cases more pronounced in the media and to a lesser extent in the
neointima. This upregulation is not uniform around the perimeter of the artery (Figure 27), and
there are loci where the protein is more upregulated in the media, other loci where the
upregulation is greater in the neointima, and loci where both media and neointima seem to have
the same expression of the protein. FKBP-12 expression around the perimeter matches that one
of b-Tubulin, but is of a lesser extent. In the control, native arteries the expression of both
proteins is uniform around the perimeter.
Similarly to proteins in diseased arteries, the lipid is nonuniformly distributed around the
perimeter (Figure 26). Because lipid staining is done only in frozen sections and b-tubulin and
FKBP-12 staining was only available in paraffin sections, no correlation between protein
expression and lipid presence could be drawn at this time. However, there are some other
correlations that could be drawn. Areas that are low in b-Tubulin are vacuolated areas where
lipid used to reside (and was dissolved during paraffin processing), best seen in the H&E,
Verhoeff, or PS red stained sections (Figure 28b,c,d). Areas that are high in b-tubulin correlate
with the areas high in macrophages (Figure 28e,f).
3.3.5 Rabbit Abdominal Aorta: 5-month high fat diet
Having in place the techniques for assessing drug deposition, via FITC-labeled Paclitaxel, and
ultrastructure by histological staining, we proceeded to look for correlations between drug
deposition and ultrastructure. A 5-month model was used because (1) this model was
hypothesized to have developed a higher stage of atherosclerosis than the 1-month model and
would thus provide for greater differences between disease and control, and also be more
relevant to a clinical scenario, and (2) the specimen were available. Full-artery histology and
drug images used for this study are given in the Appendix. A summary of histology and drug
deposition in a 5-month control artery (Figure 29, a-e) reveals (1) high concentration of collagen
in the adventitia (bright yellow or green in Figure 29b) and low in the neointima and media, (2)
high concentration of b-tubulin in most of neointima (brown in Figure 29c) and low in most of
media and low in adventitia, (3) moderate elastin in the media (black fibers in Figure 29d) and
low in neointima and adventitia, and (4) high Paclitaxel concentration in the neointima (bright
green in Figure 29e), moderate in the media, and low in the adventitia.
A summary of histology and drug deposition in a 5-month diseased artery (Figure 30, f-j) reveals
(1) high concentration of lipid in neointima or media or both (red in Figure 30f) and little in
adventitia, (2) high concentration of collagen in adventitia (bright yellow, green, or pink in
Figure 30g) and lower in media and neointima, (3) some tubulin in NI or M and low in adventitia
(brown in Figure 30h), (4) some elastin fibers in the media (back fibers in Figure 30i) and no in
NI or adventitia, and (5) low Paclitaxel concentration throughout the artery (lack of bright green
in Figure 30j). A more detailed look at the lipid and drug reveals that drug deposition is higher
in the areas that are low on lipid, for example in the media relative to the neointima (Figure
31b,c). That is not always the case however (Figure 31d) indicating that other ultrastructural
elements may be important in determining drug deposition.
Drug vs. Lipid
Taking a 3-section average of drug intensity around the perimeter, and in each compartment,
demonstrates that drug intensity in the control artery is higher than the intensity in the diseased
artery (Figure 32). A 3-section average of the lipid content indicates a significant non-
uniformity (large error bars) and highest lipid content in the neointima, lesser in the media, and
least in the adventitia. If the difference in drug deposition between the control and the diseased
artery in each compartment is plotted against the lipid difference (this is the lipid content of the
diseased compartment, as the control artery has no lipid) a potentially linear relation is obtained
(Figure 33). Because of high variability in lipid, a 3-section average is not an adequate measure
of lipid content around the artery (which had been constructed using 19 sections) needs to be
reevaluated using a different method explained in Chapter 5.
Drug vs. Collagen or Elastin
Using a 3-section average around the artery for drug deposition vs. collagen content yields an
exponentially decreasing profile (Figure 34). The same method for elastin, when all
compartments and the control internal elastic lamina are include and the control neointima are
excluded, yields a direct and a linear relationship (Figure 35). The fact that the noontime drug
deposition in the control artery is different from the rest of data indicates that something other
than elastin is binding drug in this compartment (potentially tubulin). Related, preliminary data
by Tzafriri & Brazin have revealed strong Paclitaxel binding to elastin isolated from calf carotid
arteries, where strong refers to 40-fold higher binding to elastin than the arterial tissue as a
whole.
Drug vs. Tubulin
Using a 3-section average around the artery for drug deposition and the whole-compartment
average for b-tubulin content an increasing and fairly linear correlation between drug and tubulin
is obtained (Figure 36).
3.4 Discussion
Human and rabbit atherosclerotic tissues were examined to understand how ultrastructural
changes that occur with disease affect locally delivered drug deposition and distribution.
3.4.1 Tissue States Used for Drug Uptake and Distribution
Samples of human abdominal aorta were obtained from autopsy cases with diagnosed
atherosclerosis. After cleaning and, in some cases, separation into tunica layers, arterial samples
were used for drug incubation and histology. All tissue specimen had modest to significant lipid
deposits, and no thrombi, with scattered areas of necrosis or calcifications.
Drug distribution was also examined in balloon catheter-denuded aortae and iliac arteries from
rabbits maintained on a normal diet or after 4 weeks of a diet rich in cholesterol and oil. In all
cases arterial injury was performed 2 weeks into the high fat diet, and in some tissues were
harvested after an additional 2 weeks of the diet, and in others after an additional 10 weeks, the
last eight of which were on normal chow. Not unexpectedly balloon denudation induced intimal
hyperplasia exacerbated in the presence of high fat diet. In these latter animals lesions were not
only of greater mass but contained lipid infiltrates in the neointima and media as well. The
disease process was more pronounced in the iliac arteries than the aorta as the 3 Fr balloon that
was used for endothelial denudation inflicted a greater injury in the iliac arteries than in the
abdominal aorta. The longer term survival animals not only exhibited lipid and neointima but
areas of calcification and necrosis with a disruption of the regular elastin ultrastructure in the
media. The more prolonged time allowed for greater disease progression even in the absence of
cholesterol diet after the first month.
3.4.2 Changes in Drug Deposition and Distribution with Disease
Examination of drug deposition at three successive levels of resolution allowed for an
understanding of the colocalization of binding and drug penetration and deposition. We report on
the drug at the bulk tissue level, the compartmental level (with neointima, media, and adventitia
separated), and the local (micron) level.
Bulk Changes (radiolabeled PXL, EVE)
Human and Rabbit Tissues were used to asses drug deposition at the bulk level. Whole artery
samples were incubated in drug solutions until equilibrium and assessed for drug content.
Human Tissue
The presence of a lipid-rich core, devoid of smooth muscle cells and elastin, and increased
collagen content distinguished "late" from "early" lesions of human atherosclerosis (Figure 15).
Given that paclitaxel and everolimus deposition was significantly lower in the "late" than in the
"early" lesion (Figure 16, 22% decrease for PXL and 14% for EVE) we conclude that high
content of lipid and collagen and low content of elastin and cells led to decreased drug deposition
in the "late" lesion. Decrease in drug deposition was more pronounced for paclitaxel than for
everolimus, implying that paclitaxel has a greater affinity for elastin or cells or a lower affinity
for lipid and collagen, than does everolimus.
Rabbit Tissue (1-month Model)
Examination of rabbit atherosclerotic tissue supplemented and extended findings from human
tissues, as the animal model provided greater control over lesion type and size, and was more
abundant. Tissue drug deposition in these arteries also showed lower drug levels with disease,
although the decrease was not statistically significant on a bulk tissue level (Figure 21). This
decrease was more pronounced for paclitaxel than for everolimus (21% decrease for PXL and
12% for EVE),. The lack of statistical significance could be due to a number of reasons. In the
first case, the lesion formed and harvested one month post-intervention is in early stages of
disease, where structural changes relative to the control injured artery may be insufficient to alter
drug deposition significantly. Indeed, everolimus deposition in the early stage rabbit lesions was
greater than in the more advanced disease of human tissue. Paclitaxel deposition was similar in
the rabbit model and in the human tissue. This differential effect may which may be explained by
identity of Everolimus bulk concentration in both experiments (10-6M) and use of a Paclitaxel
bulk concentration one order of magnitude greater in the rabbit experiment (10-8M) than for the
human experiment (10-9M). Secondly, significant changes that may exist on the local level may
be masked when drug deposition is assessed and then averaged on the bulk level. As a result it
became evident that examination of tissue structure at a more magnified level needed to be
considered to determine if there was an impact of ultrastructure on drug deposition.
Compartmental Changes (radiolabeled PXL, EVE, RAPA)
When the human artery was separated into its three tunica layers, the neointima that was rich in
lipid and poor in smooth muscle cells (SMCs) showed lower drug deposition than the media or
the adventitia (Figure 19). Cholesterol content, defined as the sum of free and esterified
cholesterol, was highest in the neointima, and lower in the adventitia and the media. Drug
deposition tracked inversely with cholesterol content, i.e. it was highest in the media, then
adventitia, and lowest in the neointima. The reduction in deposition between the media and the
neointima was higher for paclitaxel than everolimus or rapamycin, indicating that paclitaxel is
excluded more than the other two drugs from lesions of high cholesterol content. On the whole,
differences in drug deposition among the three tunica layers indicate that there are structural
differences across the human abdominal aorta that guide the level of drug deposition.
Fine Changes (radiolabeled PXL, EVE)
Immunostaining for b-tubulin and Oil-Red-O staining for lipid showed variability in the radial
and angular direction of an arterial cross-section in the 1-month rabbit model (Figure 27 and 26,
respectively). As both elements are hypothesized to have an effect on drug binding, where b-
tubulin would bind the drug and lipid displace the drug, drug distribution would also be variable.
Therefore we surmised that only drug distribution profiles, or drug concentration on a local level,
could capture differences in drug deposition that occur with disease. The rabbit iliac artery was
too thin for cryosectioning, but that the abdominal aorta could be cut into 10um sections to yield
enough data points for a transmural profile. When cryosectioned, a bell-shaped distribution was
observed in both injured and diseased abdominal aortae for paclitaxel and everolimus. That
profile is most likely arises from the differential elements within the three vascular
compartments: a low-binding neointima, a high-binding media, and a low-binding adventitia.
Such morphologic discrimination was observed in the human atherosclerotic abdominal aorta as
well. The shape of the transmural profile likely tracks the distribution of drug binding sites,
which include specific binding sites represented by C-tubulin and general binding sites
represented by tissue proteins like elastin. The media is the highest-binding compartment
because it likely has the most elastin and highest density of cells, whether SMCs or infiltrating
macrophages. More details on these explanations for both drugs are given below.
Paclitaxel
In the injured artery, elastin concentration peaks in the media (Figure 29d) and b-tubulin can be
high in both the neointima and the media (Figure 29c shows the case when it is high in the
neointima). In the diseased artery, elastin also peaks in the media (Figure 30i), and that can also
be the case for tubulin (Figure 30h or 24b). This is why drug concentration peaks in the media.
In addition, high tubulin in the media may be due to macrophages rather than to smooth muscle
cells - as variability in tubulin concentration around the arterial perimeter correlates with
variability in macrophage staining (Figure 28), while SMC staining is uniform around the
perimeter. It is important to note that different drug profiles from the ones seen above can be
obtained depending on the concentrations of binding sites, which can change with vessel
remodeling and associated changes in elastin and collagen content, and particulate infiltration
such as changes tubulin content through inflammatory cell infiltration and lipid content.
One major histological difference between the diseased and the injured artery is in the lipid
infiltrates. We hypothesize that these lipid infiltrates, typically present in the neointima or inner
media, have lower affinity for the drug than do tubulin and elastin (experiments are in progress
in our laboratory to test this hypothesis). Lipid displaces drug binding elements like tubulin and
elastin uniformly across the artery, thus lowering drug deposition levels uniformly across. Given
the highest lipid concentration in the neointima and part of media, the peak of the drug profile is
shifted away from the neointima and deeper into the media, for a diseased artery. In addition,
low tubulin content does not have to be due to the presence of lipid infiltrates, but any infiltrates
that would reduce the cellular concentration. This is inferred from Figure 28, where areas high
in tubulin are high in macrophages, while areas low in tubulin are not necessarily high in
vacuoles (lipid remnants).
Everolimus
For injured and diseased arteries, the drug deposition pattern could be explained in a similar way
as for Paclitaxel, assuming everolimus high elastin binding, and high cellular binding to an
intracellular target FKBP-12, in the media. The lipids, however, do not seem to affect the
Everolimus profile. There are at least three possible explanations for this observation:
1. insufficient amount of lipid infiltrates: the samples for everolimus profiling, relative to
those for paclitaxel, were taken at a more proximal locus in the aorta, with potentially less
balloon injury and less dense lipid infiltrates,
2. everolimus affinity for lipid relative to elastin or FKBP-12, could be about the same, and
3. drug instability, which is a function of the drug shelf life and the solvent. The
radiolabeled drug was supplied in toluene and needed 2% PEG-200 for stability in an aqueous
solution. The duration of stability in an aqueous solution wasn't known, while the duration of
our experiment was 2-4 days .
Fine Changes (FITC-Iabeled PXL)
To explain drug transmural profiles and correlate them with ultrastructure a new method, that
utilizes a FITC-Iabeled paclitaxel conjugate (Paclitaxel Oregon Green 488, Bisacetate), was
developed.
Native arteries
The pattern of FITC-Iabeled paclitaxel conjugate distribution in a native artery at room
temperature was different from the pattern at 37C. At the room temperature (Figure 14a) most
of drug was bound to thread-like structures, thought to be elastin. This binding would be
representative of the general and non-temperature dependent binding. Specific binding to
microtubules may be low, as microtubule structural integrity is compromised at temperatures
below 37C. At 37C (Figure 14b), the drug (in green) is more uniformly distributed throughout
the artery than at the room temperature. The low drug concentration in the middle of the artery
is either due to (a) non-equilibrium distribution, where drug did not have enough time to
penetrate and saturate the artery during the 24hr incubation period, or (b) a variability in the
concentration of binding sites. The conclusion however is that drug distribution profiles the
room temperature and 37C are different, because at 37C a greater amount of tubulin is in the
form of microtubules, creating a greater number of specific binding sites for Paclitaxel binding
(general binding sites are assumed to be available at both temperatures).
Injured arteries (5-month model)
When FITC-paclitaxel was delivered to injured arteries, there was a relative uniformity in drug
deposition in each compartment around the perimeter. There was also uniformity in collagen
and elastin distribution, the first being high in the adventitia and the second high in the media.
Tubulin distribution, however, showed some variability. Therefore, any variability in drug
distribution is more likely attributable to tubulin than other mural proteins. Tubulin and drug
distribution could not be directly compared on a point-by-point basis as tubulin staining was
performed in a paraffin-embedded sample, while drug (as well as collagen, elastin, and lipid
content) was viewed in frozen sections.
On a compartmental basis (i.e., comparing neointima with media or adventitia), the injured artery
showed highest paclitaxel deposition in the neointima, lower in the media, and least in the
adventitia (Figure 32). Collagen was predominantly found in the adventitia and elastin in the
media. On a compartmental-average basis, tubulin was found at the highest level in the
neointima, lower in the media, and least in the adventitia. Therefore, the high drug concentration
in the neointima is most likely due to tubulin. This tubulin may be present in SMCs, but also in
infiltrating cells like macrophages.
Diseased arteries (5-month model)
There was a greater variability of ultrastructure around the perimeter of arteries harvested five
rather than one months after injury, and as a consequence greater variability in drug distribution.
There were areas consistent with an earlier stage of disease (Figure 31 b, c) and areas consistent
with a later stage of disease (Figure 30j, 3Id). The latter also included calcification in the media,
shown as void space (Figure 3Id). Areas high in lipid (neointima in 13b-c, and neointima plus
media in 13d) were low in drug, and areas without lipid (media in 13b-c) were high in drug. In
addition, areas high in drug appeared to bind drug through binding to elastin - elastic fibers
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showed as intense green (Figure 31, a-c). At this point, without considering tubulin and
collagen, a conclusion is that drug localized to areas replete with elastin and relatively devoid of
lipid and calcification. Because of variability in ultrastructure, we proceeded to correlate drug
with ultrastructure on a local basis within compartments (correlations that occur locally could not
be captured on a compartment average basis). Although different ultrastructural elements affect
drug deposition simultaneously, and possibly in different directions, some trends between drug
and ultrastructure became apparent. Increased content of cross-linked collagen tended to
decrease paclitaxel deposition (Figure 34). Cross-linking possibly physically retards drug
penetration into the collagen structure, or positively and negatively charged side-chains of
collagen have chemically low affinity for a hydrophobic molecule like paclitaxel. Increased
elastin content showed strong positive correlation to increased drug deposition, when the
neointima of the injured artery was not included in the analysis (3 circled points in Figure 35).
Neointima of the injured artery has little elastin, yet it shows high drug content. That could be
the case, if another binding element like tubulin is also present in the neointima and binds the
drug in that region. Regarding paclitaxel and elastin binding, there are preliminary data in our
laboratory to indicate high affinity of elastin for paclitaxel. Elastin isolated from calf carotid
artery binds paclitaxel at a several fold higher level than the artery. Increased b-tubulin content
(Figure 36) also leads to increased drug deposition, a fairly intuitive result as microtubules that
are build from b-tubulin dimer units, are known to specifically bind paclitaxel.
3.4.3 Experimental Limitations and Suggestions
The findings presented here on how ultrastructure affects FITC-labeled paclitaxel deposition can
be reinforced by the studies of a native artery and studies of the 1-month rabbit model (with
injured and diseased arteries ). The 1-month model would yield clearer conclusions than the 5-
month model, because there would be less destruction of the tissue architecture by necrosis and
calcification. Consequently, content of certain ultrastructural elements (like elastin) would be
higher, allowing for stronger drug vs. ultrastructure correlations. More suggestions on future
directions are given in Chapter 5.
3.4.4 Conclusions
Given that arterial tubulin and elastin likely bind the drug, while arterial lipid, collagen, and
calcium exclude the drug from an artery, the following conclusions could be drawn about the low
drug deposition in the diseased artery. In the diseased artery, there was slightly more drug in the
media than in the neointima or adventitia. This could be the case because of two possibilities:
(a) elastin presence in the media (and its lack in the neointima and adventitia) contributes to drug
binding in that compartment, and (b) the high concentration of lipid in the neointima and
collagen in the adventitia leads to lesser drug deposition in those two compartments. Media has
also relatively low drug deposition because of lipid infiltrates and calcifications.
The findings presented here could be developed further to be a valuable tool in the clinic. Using
lesion ultrastructure, that could be measured by imaging techniques noninvasively and in real
time in the near future, an algorithm that would correlate drug deposition with ultrastructure, and
knowing the biologic effect as a function of drug tissue concentration, an endovascular implant
with an optimal drug dosing could be selected for each patient.
Figure 13 FITC-Paclitaxel technique for colocalization of drug & ultrastructure
(calf carotid artery):
(a) Paclitaxel-saturated artery shows no background or autofluorescence. (b) Sample incubated
in FITC-labeled PXL (10-7M) for 24hrs shows drug in green. (c) Sample incubated in PXL (10-
6M) for 24hrs followed by FITC-labeled PXL (10-7M) for 24hrs shows no green. In all images,
cell nuclei are DAPI-stained blue.
Figure 14 FITC-PXL in native Rabbit AA
(a) at room temp, general binding is shown in green (nuclei are blue), (b) at 37C, total (general &





Figure 15 The Human AA model of atherosclerosis (histology).
"Early lesion" sample is shown in panel-1 and "Late lesion" sample in panel-2. (a) Oil-Red-O
stain for lipid, (b) Picrosirius Red stain for collagen, (c) a-actin stain for smooth muscle cells
(brown), and (d) Verhoeff stain for elastin (black). In both samples, lipid and collagen are
present throughout the artery, while cells and elastin are present in the media and not in the












Figure 16 Total Uptake Capacity (TUC) in the human AA (whole-artery samples)
TUC of Paclitaxel and Everolimus in "early" and "late" lesions.
Both drugs show decrease in deposition with increased lesion complexity, and in the case of
Paclitaxel the decrease is greater.
i
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Figure 17 The Human Abdominal Aorta model of atherosclerosis (I)
Samples of human abdominal aorta were obtained from autopsy cases within 24hrs
post-mortem. Whole-artery samples (w) were used for drug incubations. Areas that
contained "early lesions" (light beige in color and firm on palpation, (1)) were used
separately from those that contained "late lesions" (yellow/orange in color and hard
on palpation, (2)).
Figure 18 The Human Abdominal Aorta model of atherosclerosis (II)
(a) An arterial sample that uniformly separated into 3 constituent compartments (NI, M, and A).
(b) A sample that didn't separate into it's constituent compartments and consequently
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Figure 19 Total Uptake Capacity in the human AA - compartmentalized.
TUC of selected drugs in different compartments (tunica layers) is a function of the
compartmental cholesterol content. Paclitaxel deposition is most sensitive to cholesterol content,
which led to mechanistic studies using this drug alone.
Figure 20 The Rabbit I-month Abdominal Aorta model of atherosclerosis
Animal fed normal diet for 4-weeks and balloon-injured at 2-weeks.
(b) Animal fed CHL/peanut oil enriched diet for 4-weeks and balloon-injured at 2-weeks.
Neointima is present in both arteries, and lipid infiltrates (in red) only in the second artery (b).
Both neointima and lipid infiltrates are thought to alter drug deposition, relative to a native















Figure 21 Total uptake capacity (TUC) in the rabbit abdominal aorta.
TUC for Control (injured + normal diet) and Diseased (injured + CHL/oil diet) arterial samples.
There is a modest decrease in drug deposition from control to diseased case. These bulk
measurements are thought not to adequately demonstrate the local drug differences.
I
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Figure 22 Transmural distribution of paclitaxel in the rabbit abdominal aorta
Arterial samples incubated until equilibrium, and drug allowed to diffuse into the sample
From all sides. TUC of 20-micron sections, from the luminal to the adventitial side of
control (injured + normal diet; blue) and diseased (injured + CHL/oil diet; orange)
arterial samples, demonstrates local drug deposition differences between control and
disease. In disease, drug deposition is lower and more uniformly spread, likely tracking
































Figure 23 Transmural distribution of everolimus in the rabbit abdominal aorta
Arterial samples incubated until equilibrium, and drug allowed to diffuse into the sample
from all sides. TUC of20-micron sections, from the luminal to the adventitial side of
control (injured + normal diet; blue) and diseased (injured + CHL/oil diet; orange)
arterial samples, demonstrate no local drug deposition differences between control and
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Figure 24 The Rabbit 1-month Iliac Artery model of atherosclerosis
Native ((a), (c)) and diseased ((b), (d); CHL-enriched diet for 4-weeks and balloon-injury at 2-
weeks) Rabbit Iliac Arteries. Increased concentration of Tubulin and FKBP-12 are seen with
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Figure 25 The Rabbit 1-month Iliac Artery model of atherosclerosis
Rabbit Iliac Artery, Diseased (animal fed CHL-enriched diet for 4-weeks and
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e. f. a-actin & RAM-11
Figure 28 Variability in Ultrastructure around the Perimeter in Diseased Arteries
High tubulin concentrations (a) correspond to areas high in macrophages (e), and low tubulin




Figure 29 The Rabbit 5-month Abdominal Aorta model of atherosclerosis
Control artery (injury + normal diet): (a) oil-red-O stain for lipid. (b) Picrosirius red stain for
collagen shows as bright green, yellow, and pink under polarized light; (c) tubulin immunostain









Figure 31 FITC-PXL (green) and lipid (inset, red)
Distribution in the rabbit 5-month model:
















Figure 32 FITC-PXL deposition relative to lipid content
(a) Control (normal diet + injury, ) artery shows greater Pxl deposition than the
diseased artery (injury + CHL/oil diet). (b) Greater difference between the control and diseased
artery drug deposition in each compartment corresponds to greater lipid content.
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Figure 34 FITC-PXL deposition relative to collagen content
Control (normal diet + injury) artery vs. diseased artery (injury + CHL/oil diet).
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Figure 35 FITC-PXL deposition relative to "elastin content"
Control (normal diet + injury) artery vs. diseased artery (injury + CHL/oil diet).
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Figure 36 FITC-PXL deposition relative to b-tubulin content
Control (normal diet + injury) artery vs. diseased artery (injury + CHL/oil diet).
Both drug series normalized to the same low value.
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CHAPTER 4: Drug Release Kinetics from Stents in Vivo
4.1 Background, Hypothesis, and Specific Aims
Background
Percutaneous coronary intervention is a widely used procedure in the therapy of patients with
coronary artery disease that has evolved dramatically over the past decade. Balloon angioplasty
has given way to endovascular stents and stents to drug eluting implants. Patients with acute
coronary syndromes as well as chronic obstructive coronary artery disease partake of this
technology. The evolution has been sparked by the spirit of innovation and rapid acceptance of
these technologies but also by the complications that emerge with each expected "fix". Balloon
angioplasty for example can percent coronary artery bypass surgery in many patients but acute
vascular recoil and the later in growth of reactive tissue requires that up to 60% of patients
require some additional procedure. Endovascular stents prevent the acute recoil but induce a
complex and resilient tissue restenotic response that is significant in 20-40% of patients.
Considerable effort has been put into developing pharmacologic strategies to combat restenosis
based on the pathophysiologic mechanisms underlying the development of restenosis, which
primarily involves an inflammatory reaction followed by smooth muscle cell proliferation. One
way to deliver anti-restenotic drugs has been through the use of local drug delivery with the aid
of drug coated stents. This has had the benefit of delivering effective levels of drugs while
limiting the potential for systemic toxicity. However, little has been known about the local
pharmacokinetics and pharmacodynamics of stent-based drug delivery.
Hypothesis
As arterial drug deposition, retention and distribution involves a series of kinetic events
including binding, the kinetics of drug presentation is an important parameter in drug eluting
stents.
Specific Aims
The specific aim of this study was to examine the impact of the drug release kinetics on tissue
deposition. We proceeded to evaluate the temporal and spatial distribution of ABT578, a
rapamycin analog, delivered from endovascular metal stents (coated by radioactively labeled 3H-
ABT579) implanted into rabbit iliac arteries. The experiments used the New Zealand White
rabbit model that has been well characterized previously in our laboratory. The protocol
included animals sacrificed Iday, 3days, 7days, 14days, and 28 days after implantation. The
amount of drug present in the rabbit right and left iliac arteries (stented, proximal, and distal
segments, and adventitia) and solid organs (brain, liver, kidney, spleen, carotid artery, gonad,
heart, lung, and intestine) was determined at the above time points.
4.2 Materials & Methods
4.2.1 Device Description
Stents, 15 mm long 3.0 mm in diameter, were coated with a phosphorylcholine (PC) polymer
loaded with tritiated drug at a concentration of 100 ug/stent. The specific activity of the drug
was 20 uCi/mg for a total of 2uCi/stent. Stents were supplied in both a simple coated design as
well as an overcoated design (Figure 37). The overcoated design employs a second non-drug
containing layer implanted over the first in order to delay release.
4.2.2 Animal Model
Using experimental protocols that conform to the Code of Federal Regulations 21 part 58
Good Laboratory Practices for Nonclinical Laboratory Studies, which are identical to those we
have used in prior experiments and published extensively, the experiments were performed in
AAALAC (American Association for the Accreditation of Laboratory Animal Care) certified
facilities. All animal protocols were evaluated and approved by IACUC (Internal Animal Care
and Use Committee) of the Harvard Medical Area. All animal and surgical facilities conform to
the NIH (National Institute of Health) guide. The animals were housed in the facility-approved
cages under sanitary conditions, provided rabbit chow according to normal diet, and water ad
libitum. Food was withheld the night before surgery.
New Zealand White male rabbits were chosen as the experimental species for this study because
of the relative ease of handling of these animals. In addition, the rabbit iliac arteries are large
enough to accept the commercially available stents used in humans, and the experience of the
laboratory with this model allows for successful implantation and evaluation of model related
procedures. Animals were approximately 3 months old, and weighed 3.5-4 kg. Animals were
received and identified by the technical staff of the ECI lab and given a unique lab number. All
animals were obtained from Mills Brook Farms, a vendor accepted by the IACUC.
Stent Placement
A total of Eight New Zealand White rabbits were used for the experiment at each time point.
Out of the eight animals at every time point, four received Overcoat (0) stents, and the other four
received No-Overcoat (NO) stents. In rare instances, where an animal had died before the time
was reached (one animal in the 3 day-NO group and one animal in the 14 day-O group), the
analysis was performed on seven instead of eight animals for the given time point. In all groups,
each animal received two identical stents, one in each iliac artery. To reduce the incidence of
early occlusive thrombosis, aspirin was added to drinking water (5 mg/kg) starting one day
before surgery and continued throughout the experiment (until sacrifice). Each animal received
an injection of Ketamine (35mg/kg) and Xylazine (5 mg/kg) to induce general anesthesia. If
additional anesthesia was required during surgery Isoflurane (0.1 % to 5.0% to effect) with
oxygen was administered via a mask.
Surgical Procedure
The animal was shaved and the surgical site prepped in sterile fashion with alcohol and Betadine
(disinfectant and anesthetic). The femoral cutdown consisted of an incision,...,2 cm in length. The
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muscle was spread through blunt dissection and the femoral artery isolated. The artery was
ligated distally. Control ties were applied proximally and a bolus of heparin (100 U/kg) was
given IV at this time. A small arteriotomy was made into the artery and a three French fogarty
balloon catheter placed into the lumen of the vessel. The Fogarty catheter was advanced
approximately 20cm and inflated with 0.55cc of air via syringe and drawn back until it reached
the arteriotomy and then was deflated. This step was repeated three times on each side (Figure
38).
After the vessel was denuded with the Fogarty catheter, a stent balloon system was introduced
into the iliac artery. Using fluoroscopy, the stent balloon system was advanced into the iliac
artery beyond the inguinal ligament and deployed at 10 atmospheres for 30 seconds. The
femoral artery was tied off using the proximal control ties and the incision closed using vicryl
sutures.
Animals received a bolus of Buprenex post operatively (0.005 mg/kg IM), and, if necessary,
another bolus 24 hrs later. The animals were assessed for pain using the following criteria:
mobility, appetite, vocalizations, general appearance, and attitude. The animals were checked by
the Technical Staff of the ECI Laboratory, and if any problems arose, the investigator and the
veterinary staff were consulted.
Tissue and Organ Harvest
At the time of sacrifice, animals were anesthetized with xylazine 2.0 mg/kg IM) and sacrificed
with an intravenous injection Nembutal. The inferior vena cava was cannulated and perfused
with Ringer's lactate solution. Stented arteries were harvested as well the arterial tissue
immediately proximal and distal to the stented region (Figure 39). Arterial adventitia was
harvested along with samples of the following organs: brain, liver, kidney, spleen, carotid artery,
gonad, heart, lung, and intestine. One animal without stent implantation was harvested for
purposes of assessing background tissue activity.
4.2.3 Tissue Analysis for Drug Content
Tissue samples were dried in a convection oven for 24hrs, weighed, and digested by the Solvable
solution overnight (16 hrs). Subsequently, hydrogen peroxide was added (to bleach out the
tissue color), and the samples were incubated at 55-65L C for one hour. Following bleaching,
Hionic Fluor scintillation cocktail was added, and the samples left to equilibrate to room
temperature and light for one hour. Radiation content was determined by Liquid Scintillation
Counting (LSC). A detailed protocol of this procedure is given in Appendix. Tissue
concentrations are generally reported as Eg drug per g tissue. In the case of the stented section of
the artery where the entire sample was collected (rather than a portion of the whole) we also
report tissue levels as percentage drug released.
4.2.4 Statistical Analysis
Statistical analysis was performed using one-way analysis of variance (ANOVA) utilizing a
Bonferroni correction where multiple comparisons are made. Values are given as mean ± SE. P <
0.05 was considered significant.
4.2.5 Radioactive Material Disposal
Each animal cage had a cage pan to trap the urine and feces of each individual animal. The cage
pan was lined by the absorbent padding to trap the urine and feces. Urine and feces were
assumed radioactive and disposed as radioactive waste three days post-stenting. All bodily
tissues that were harvested were disposed of in the radioactive waste in LMRC (Longwood
Medical Research Center). Since the radioactivity that was present in animals at the end of
experiment was less then 0.5E Ci per gram body weight the animal carcasses were disposed of in
the normal fashion.
4.2.6 Mathematical Description of Drug Deposition Profiles
A two-compartment model (Figure 40) was chosen to mathematically describe drug tissue
deposition, given the two stent release platforms. Drug enters the tissue compartment after being
released from the stent. This tissue compartment ("control volume") is defined as tissue adjacent
to the stent and includes the arterial wall in the radial direction and the in-stent segment in the
axial direction (presented in the figure by a dashed box). Stent release kinetics are given by
"dM/dt", and the fraction of drug released that enters the tissue compartment is given by "f'.
Within the tissue compartment, the drug can exist in a free or bound form, and these two forms
are interchangeable through forward (kf) and reverse (kr) binding constants. Drug can be
eliminated from the tissue compartment (for example, by diffusion to the surrounding tissue or
by metabolism) and the rate of that process is given by the elimination constant, kel (a 1st order
elimination constant is assumed).
Parameters and Equations
dM/dt, drug release rate from stents, is obtained from experimental data by fitting the data to a
1 st-order process of the form:
M= Mmax - e - t T  (Equation-l)
Mmax is the maximal amount of drug released from the stent (at day 28) and M (cumulative
drug released at any time point) is measured at t=1, 3, 7, 14, and 28days. _, the time constant of
release, is the only unknown and can be solved for.
f and ke, the fraction of drug that enters the tissue compartment and the elimination constant,
respectively, are two results that are obtained by fitting solution to a diffusion equation to tissue
data, in the following manner.
The governing mass balance equation on the tissue compartment (control volume) is the
following, where C is the free drug concentration and B is the bound drug concentration in the
tissue:
dCdB dM
VT( +- )=f dM keC (Equation-2)dt dt dt
The amount of the bound drug, B, can be described by the following equation, where Bmax is the
maximal number of bound sites:
dBd =kf CBmax 
- B (Equation-3)dt
Assuming linear (B << Bmax) and steady state (dB/dt = 0) binding, and taking Kd = kr/kf,
Equation-3 becomes:
B
B =  C
KD
(Equation-4)
Further, the total drug tissue concentration is the sum of the free and the bound drug
concentration:
B
C,=C+B = K=l +-
C
K then becomes, using Equation-4:
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Consequently, using Equations-3 and -4, Equation-2 becomes:
dC f dM ke,




The last equation can be solved analytically, if we make the substitution C = u * e - b-t , and take
the initial condition C(t = 0)= 0, to become:
A (e-t/
c(t)= Ab-1/r - eb.t )
where A = Mmax K and
(Equation-6)
b kelK*V<
C(t) is available as experimental data (tissue drug concentration). f and kel are chosen randomly,
and C(t) is computed and termed Cm(t). Subsequently at every time point, C(t)-Cm(t) is
(Equation-5)
computed, these terms are squared and summed, the sum (of squared errors) is minimized while
allowing for changes in f and kel. This process yields a new f and kel, as well as a new Cm(t).
4.3 Results
4.3.1 Observations at Different Time Points
Observations at 1 Day
Overcoat Stents
By one day after implantation 69.2 ± 4.9 ug of the 100 ug loaded on the stents was released
(Table 1, Appendix). This represents 69.2 ± 4.9% release. An overall standard error about the
mean for the eight-stent systems examined was 7.1% of the mean value. The amount of drug
deposited in each artery was 504 ± 140 ug drug/g tissue representing 12.5 ± 2.6% of what was
released and most of the released drug at this time point was restricted to the stented area of the
artery. The amounts deposited in the proximal and distal arterial segments were about the same
(9 + 2 and 19 ± 8 ug drug/g tissue respectively). Early in release there was relatively minor
adventitial penetration of the drug (5 ± 1 ug drug/g tissue). Efficiency of arterial deposition was
8.5 ± 1.8 ug drug/g tissue/ug drug released.
Deposition into solid organs, with carotid artery excluded, was 6.9 + 0.4 ug drug/g tissue (Table
2, Appendix), which was 76-fold less than drug deposition into arterial tissue and about the same
as drug deposition into adventitia, proximal, and distal segments. No drug could be detected in
the carotid arteries (statistically significant vs. brain, liver, kidney, spleen, gonad, heart, and
intestine).
No-Overcoat Stents
By one day after implantation 74.6 ± 4.7 ug of the 100 ug loaded on the stents was released
(Table 1, Appendix). This represents 74.6 ± 4.7% release. An overall standard error about the
mean for the eight-stent systems examined was 6.3% of the mean value. The amount of drug
deposited in each artery was 726 ± 154 ug drug/g tissue representing 13.1 ± 3.2% of what was
released and most of the released drug at this time point was restricted to the stented area of the
artery. The amounts deposited in the proximal and distal arterial segments were about the same
(14 ±3 and 14 ± 5 ug drug/g tissue, respectively). Early in release there was relatively minor
adventitial penetration of the drug (9 + 3 ug drug/g tissue). Efficiency of arterial deposition was
10.3 ± 2.4 ug drug/g tissue/ug drug released.
Deposition into solid organs, with carotid artery excluded, was 6.7 ± 0.4 ug drug/g tissue (Table
2, Appendix), which is 108-fold less than drug deposition into arterial tissue and is about the
same as drug deposition into adventitia, and proximal, and distal arterial segments. No drug
could be detected in the carotid arteries (statistically significant vs. brain, liver, kidney, spleen,
gonad, heart, lung, and intestine).
Overcoat vs. No-Overcoat Comparison
At this time point there were no statistically significant differences between Overcoated and
Non-Overcoated stents with respect to stent release, arterial deposition, or efficiency of
deposition.
Observations at 3 Days
Overcoat Stents
By three days after implantation 53.0 ± 7.2 ug of the 100 ug loaded on the stents was released
(Table 3, Appendix). This represents 53.0 ± 7.2% release. It is not clear why stent release in this
four-rabbit group was measured as less than the release in the four-rabbit group sacrificed at one
day. An overall standard error about the mean for the seven-stent system examined was 13.6%
of the mean value. The amount of drug deposited in each artery was 1339 ± 413 ug drug/g tissue
representing 45.0 ± 12.6% of what was released and the bulk of the released drug at this time
point was restricted to the stented area of the artery. The amounts deposited in proximal and
distal arterial segments were about the same (128 +24 and 195 + ug drug/g tissue, respectively).
Also, at this time point, there was relatively minor adventitial penetration of the drug (25 + 12 ug
drug/g tissue). Efficiency of arterial deposition was 31.3 ± 9.9 ug drug/g tissue/ug drug released.
Deposition into solid organs, with carotid artery excluded, was 6.5 ± 1.3 ug drug/g tissue (Table
4, Appendix), which was 206-fold less than drug deposited into arterial tissue. Carotid artery
deposition (45.9 ± 10.9 ug drug/g tissue) was about 7 times more than drug deposition into other
solid organs (statistically significant vs. brain, liver, kidney, spleen, gonad, heart, lung, and
intestine).
No-Overcoat Stents
By three days after implantation 93.3 ± 1.9 ug of the 100 ug loaded on the stents was released
(Table 3, Appendix). This represents 93.3 ± 1.9% release. An overall standard error about the
mean for the six-stent systems examined is 1.8% of the mean value. The amount of drug
deposited in each artery was 531.3 + 171.9 ug drug/g tissue representing 7.0 L 2.4% of what was
released and the bulk of the released drug at this time point was again restricted to the stented
area of the artery. The amounts deposited in the proximal and distal arterial segments were
approximately the same (96.1 + 27.1 and 89.2 ± 28.4 ug drug/g tissue, respectively). There was
minor drug penetration into the adventitia (13.4 ± 1.9 ug drug/g tissue). Efficiency of arterial
deposition was 5.8 ± 1.9 ug drug/g tissue/ug drug released.
Deposition into solid organs, with carotid artery excluded, was 8.5 ±1.4 ug drug/g tissue (Table
4, Appendix), which was 62-fold less than drug deposition into arterial tissue. Carotid artery
deposition (33.7 ± 11.2 ug drug/g tissue) was about 4-fold more than drug deposition into other
solid organs (statistically significant vs. liver, kidney, and heart).
Overcoat vs. No-Overcoat Comparison
At this time point there were no statistically significant differences between Overcoated and
Non-Overcoated stents with respect to arterial deposition. However, there was statistically
significant less stent release (p=0.0002) and statistically significant greater efficiency of
deposition (p=0.03 9 ) in Overcoated stents compared to Non-Overcoated.
Observations at 7 Days
Overcoat Stents
By one week after implantation 75.6 ± 9.5 ug of the 100 ug loaded on the stents was released
(Table 5, Appendix). This represents 75.6 ± 9.5% release. An overall standard error about the
mean for the seven-stent systems examined was 12.6% of the mean value. The amount of drug
deposited in each artery was 471 ± 121 ug drug/g tissue representing 13.2 E 8.6% of what was
released and most of the released drug at this time point was still restricted to the stented area of
the artery. The amounts deposited in the proximal and distal arterial segments were about the
same (55 ±12 and 44 ±10 ug drug/g tissue, respectively). There was also minor adventitial
penetration of the drug (5 + 1 ug drug/g tissue). Efficiency of arterial deposition was 10.9 ± 6.4
ug drug/g tissue/ug drug released.
Deposition into solid organs was 4.1 ± 0.7 ug drug/g tissue (Table 6, Appendix), which was 115-
fold less than drug deposition into arterial tissue and was about ten-fold less than drug deposition
in the proximal and distal segments. There were no significant differences between carotid and
other solid organ deposition.
No-Overcoat Stents
By one week after implantation 91.5 ± 1.8 ug of the 100 ug loaded on the stents was released
(Table 5, Appendix). This represents 91.5 ± 1.8% release. An overall standard error about the
mean for the eight-stent systems examined was 2.0% of the mean value. The amount of drug
deposited in each artery was 290 + 38 ug drug/g tissue representing 2.9 ± 0.5% of what was
released. The amounts deposited in the proximal and distal arterial segments were approximately
the same (152 + 60 and 167 ± 68 ug drug/g tissue, respectively). There was minor adventitial
penetration of drug (10 ± 5 ug drug/g tissue). Efficiency of arterial deposition was 3.2 ± 0.4 ug
drug/g tissue/ug drug released.
Deposition into solid organs, with carotid artery excluded, was 3.1 + 0.6 ug drug/g tissue (Table
6, Appendix), which was 94-fold less than drug deposition into arterial tissue and approximately
47-fold less than in the proximal and distal arterial segments. Carotid artery deposition (37.4 +
13.8 ug drug/g tissue) was about 12.3 times more than drug deposition into other solid organs
(statistically significant vs. brain, liver, kidney, spleen, gonad, heart, lung, and intestine).
Overcoat vs. No-Overcoat Comparison
At this time point there were no statistically significant differences between Overcoated and
Non-Overcoated stents with respect to stent release, arterial deposition, or efficiency of
deposition.
Observations at 14 Days
Overcoat Stents
By two weeks after implantation 95.9 ± 1.4 ug of the 100 ug loaded on the stents was released
(Table 7, Appendix). This represents 95.9 ± 1.4% release. An overall standard error about the
mean for the six-stent systems examined is 1.4% of the mean value. The amount of drug
deposited in each artery was 233 + 102 ug drug/g tissue representing 3.2 ± 1.1% of what was
released, with standard error variation of 34% about the mean value. The amounts deposited in
the proximal and distal arterial segments were approximately the same (5 + 1 and 11 + 3 ug
drug/g tissue, respectively). There was minor adventitial penetration of drug (1 ± 0.17 ug drug/g
tissue). Efficiency of arterial deposition was 2.5 ± 1.2 ug drug/g tissue/ug drug released.
Deposition into solid organs was minor, 0.83 ± 0.22 ug drug/g tissue (Table 8, Appendix), which
was approximately 10-fold less than proximal and distal arterial segments. There were no
significant differences between carotid and other solid organ deposition.
No-Overcoat Stents
By two weeks after implantation 99.0 ± 0.5 ug of the 100 ug loaded on the stents was released
(Table 7, Appendix). This represents 99.0 ± 0.5% release. An overall standard error about the
mean for the six-stent systems examined was 0.5% of the mean value. The amount of drug
deposited in each artery was 23 ± 7 ug drug/g tissue representing 0.3 ± 0.1% of the amount
released from the stent. The amounts deposited in the proximal and distal arterial segments were
approximately the same (12 + 8 and 4 ± 1 ug drug/g tissue, respectively). There was minor
adventitial penetration of drug (1 + 0.03 ug drug/g tissue). Efficiency of arterial deposition was
0.2 ± 0.1 ug drug/g tissue/ug drug released.
Deposition into solid organs was minor, 0.62 ± 0.08 ug drug/g tissue (Table 8, Appendix), which
was approximately 37-fold less than drug deposition into arterial tissue and 13-fold less than
deposition into proximal and distal arterial segments. There were no significant differences
between carotid and other solid organ deposition.
Overcoat vs. No-Overcoat Comparison
At this time point there were no statistically significant differences between Overcoated and
Non-Overcoated stents with respect to stent release, arterial deposition, or efficiency of
deposition.
Observations at 28 Days
Overcoat Stents
By one month after stent implantation 96.5 ± 0.8 ug of the 100 ug loaded on the stents was
released (Table 9, Appendix). This represents 96.5 ± 0.8% release. An overall standard error
about the mean for the eight-stent systems examined is 0.8% of the mean value. The amount of
drug deposited in each artery was 16 ± 7 ug drug/g tissue representing 0.7 ± 0.2% of what was
released, which was approximately seven fold more than what was present in the proximal and
distal arterial segments (21 ± 6 and 50 + 31 ug drug/g tissue, respectively). Between two and
four weeks, there was minor adventitial penetration of the drug (19 ± 11 ug drug/g tissue.
Efficiency of arterial deposition was 0.2 ± 0.1 ug drug/g tissue/ug drug released.
Deposition into solid organs, 4.0 ± 1.6 ug drug/g tissue (Table 10, Appendix), was 4 fold less
than deposition in arterial tissues. There were no significant differences between carotid and
other solid organ deposition.
No-Overcoat Stents
By one month after implantation virtually all drug had been released from the stent, that is, 99.6
+ 0.2 ug of the 100 ug loaded on the stents was released (Table 9, Appendix). This represents
99.6 ± 0.2% release. An overall standard error about the mean for the six-stent systems
examined was 0.2% of the mean value. The amount of drug deposited in each artery was 54 ±
22 ug drug/g tissue representing only about 0.23 ± 0.07% of what was released and was about
the same as the amount of drug deposited in proximal and distal arterial segments (11 + 7 and 13
± 4 ug drug/g tissue). Efficiency of arterial deposition was 0.6 ± 0.2 ug drug/g tissue/ug drug
released.
Deposition into solid organs was 3.8 ± 0.8 ug drug/g tissue (Table 10, Appendix), which was
approximately 14-fold less than drug deposition in arterial tissues. There were no significant
differences between carotid and other solid organ deposition.
Overcoat vs. No-Overcoat Comparison
At this time point there were no statistically significant differences between Overcoated and
Non-Overcoated stents with respect to arterial deposition, or efficiency of deposition. Stent
release from Overcoated stents was less than Non-Overcoated stents which was statistically
significant but small (96.5 ± 0.8 vs. 99.6 ± 0.2%, p=0.029).
4.3.2 Drug Release from Stents
Release of drug from No-Overcoat stents was greater than 90% complete by day 3 whereas
Overcoated stents did not reach greater than 90% release until 14 days (Figure 41). Statistical
analysis revealed a significantly higher drug release from Non-Overcoated stents at 3 days (91.4
± 1.8 vs. 75.5 + 9.5%). At 28 days, stent release from Overcoated stents was less than Non-
Overcoated stents which was statistically significant but small and likely clinically meaningless
(96.5 ± 0.8 vs. 99.6 ± 0.2%). A first-order fit to the data revealed the following time constants of
release: t = 0.75 for the No-Overcoat case and .t=- 1.95 for the Overcoat case. Smaller time
constant indicating faster release kinetics corresponds to the No-Overcoat case.
4.3.3 Arterial deposition
Arterial deposition peaked in the No-Overcoat stents at 1 day with a concentration of 726 ± 154
ug drug/g tissue (Figure 42). By day 14 levels were close to baseline. In contrast, implantation
of Overcoated stents led to a peak arterial concentration of 1339 ± 413 ug drug/g tissue at 3
days. By day 28, levels were close to baseline. Statistical analysis revealed a near-significant
trend towards higher deposition from Overcoated stents at 3-28 days. However, when calculated
as efficiency of deposition as measured by ug drug/g tissue/ug released, there was a significant
difference between the groups with higher efficiency of deposition from Overcoated stents at 3
days (31.3 ± 9.9 vs. 5.9 +1.9 ug drug/g tissue/ug).
4.3.4 Other deposition
Adventitial and peri-stent arterial deposition. Deposition of drug into adventitial and peri-
stent arterial segments represented only a small fraction of the drug released. In Overcoated
stents, adventitial levels peaked at 3 days with a concentration of 25 ± 12 ug drug/g tissue. In
Non-Overcoated stents, adventitial levels peaked at 28 days with a concentration of 19 ± 11 ug
drug/g tissue. Proximal and distal arterial segment deposition was higher than adventitial levels
but was significantly lower than stented arterial segments. In Overcoated stents, proximal and
distal arterial levels peaked at 3 days (128 ± 24 and 195 ± 64 ug drug/g tissue, respectively). In
Non-Overcoated stents, proximal and distal levels peaked at 7 days (152 + 60 and 167 ± 68 ug
drug/g tissue, respectively).
Organ deposition. Deposition of drug into organs was in no case higher than 46 ± 11 ug
drug/g tissue (carotid artery at 3 days post implantation in Overcoated stents). However, an
interesting pattern emerged with respect to deposition in the carotid artery. At 1 day after
implantation, deposition into carotid artery tissue from Overcoated stents was approximately 3
fold less than other organs (excluding lung) which was statistically significant. In No-Overcoated
stents, carotid artery deposition was approximately 4.5 fold less in other organs which was
statistically significant. In contrast, at 3 days, deposition in carotid artery tissue from Overcoated
stents was approximately 7.3 times greater than other organs which was statistically significant.
Deposition in carotid artery tissue from No-Overcoated stents was approximately 4.3 times more
than other organs although this reached statistical significance against liver, kidney, and heart
only. At 7 days, there was no significant difference between carotid and other organ deposition
in Overcoated stents, but in Non-Overcoated stents, carotid artery deposition was approximately
12.3 fold higher than other organs which was statistically significant. By 14 and 28 days, no
significant difference in organ deposition could be identified for either stent type.
4.3.5 Mathematical Description of Drug Deposition
Overcoat Stents
Cm(t), the calculated drug concentration in the tissue at various time points was determined as
described in the Methods section and plotted as open-squared data points connected by a dashed
line (Figure 43). The data is shown as close-squared data points connected by a solid line.
The computed :fit is close to experimental data in terms of the profile shape and absolute values -
three out of five computed points fall within the standard error of the experimental data, and all
computed points fall within the standard deviation of the experimental data. The resulting kel =
78 mm3/day and f = 0.21.
No-Overcoat Stents
Cm(t), the calculated drug concentration in the tissue at various time points was determined as
described in the Methods section and plotted as open-squared data points connected by a dashed
line (Figure 44). The data is shown as close-squared data points connected by a solid line.
The computed :fit is close to experimental data in terms of the profile shape and absolute values -
all computed points fall within the standard error of the experimental data. The resulting kel =
85 mm3/day and f= 0.10.
4.4 Discussion
Local stent-based delivery of the sirolimus analog ABT578 (zotarolimus) directed drug
principally to areas beneath stents. There was limited drug in non-stented vascular structures
(proximal and distal regions, and adventitia) or systemically into various organs. As with many
locally delivered drugs (JCI 1991) deposition is greater in vascular tissues (ex, carotid artery) as
opposed to other organ tissues. However, the level of deposition remains very low.
Overcoating the stents has a dramatic effect on local drug delivery with slower and more
efficient deposition. The overcoat prolonged release more than 4-fold and produced 64% greater
drug deposition over 28 days. The overcoat layer delays and reduces the amount of drug at the
stent-tissue interface at any given time, during the first 14 days, reducing drug washout by the
flowing blood and increasing the efficiency of deposition; the rate of drug tissue uptake is fixed
by drug and tissue properties, and independent of the stent platform.
Deposition of the released drug into the stented arterial tissue depends on three kinetic events:
the kinetics of drug presentation by the stent , the kinetics of drug absorption by the tissue, and
the kinetics of drug clearance out of the tissue. The cumulative drug deposition over the reported
28 days should be a combination of these three events and depends on which event is the rate
limiting. If drug release is rate limiting for both stents (i.e., slow), then the same percent of drug
released at any point in time should get into the tissue. Assuming slow clearance kinetics as
well, drug will accumulate and peak until no more drug influx is possible. Clearance will then
reduce drug deposition. This would happen for both stent types, and deposition profiles would
be similar in shape and magnitude, with the Overcoat stent shifted in time compared to the No-
Overcoat stent. If drug transport into the tissue is rate limiting then a stent with slower release
kinetics could lead to greater drug deposition because drug release would match what can be
accepted into the tissue. Since any excess that does not penetrate the tissue is washed out by the
flowing blood a lower percent of the released drug would be washed away by the blood, and a
greater percent would deposit into the tissue. Indeed, a greater deposition with the Overcoated
stent was seen in our experiment.
Experimentally, there was greater data variability with both the Overcoat release kinetics and the
Overcoat tissue deposition. One possible explanation is that the overcoat layer did not modulate
drug release as uniformly as was intended, for example, by getting dissolved at varying rates in
the flowing blood, or by having nonuniform drug diffusion properties.
To understand better the mechanistic difference between the two stent systems and how stent
release kinetics affect tissue deposition in each, a 2-compartmental mathematical fit to the data
was developed. In a governing 1st order differential equation of tissue concentration with
respect to time, the drug was allowed to enter into the tissue at a rate presented by the stent and
exit as a function of a clearance constant. Within tissue, drug could exist as free or bound, the
ratio of which was described by a partition coefficient that was experimentally measured for
these types of drugs in Chapter 2. The No-Overcoat model agreed with the tissue deposition data
(0.978) better than the O model (0.864). Concomitantly, tissue concentrations for the Overcoat
stent (10-5M and 10-3M) were higher than for the No-Overcoat stent (10-5M and 10-4M).
Taken together, these two sets of observations suggest that our assumption of linear binding is
adequate for the No Overcoat case, but may not be for the Overcoat case.
Two parameters were obtained as a result of fitting the mathematical description to the data.
One was the clearance rate of the drug from the tissue. There was only a small difference (of
8%) between the two stent types, which is reasonable given that the clearance depends only on
the drug, the tissue, and the control volume environment, and not on the stent type. The second
parameter was the fraction of drug released from the stent that got deposited into the tissue. A
difference of 10% for the No-Overcoat stent vs. 20% for the Overcoat stent was primarily due to
higher efficiency in drug uptake associated with slower release profile of the Overcoat stent.
Both No-Overcoat and Overcoat stents were further developed into clinical products and have
been tested in clinical trials. The No-Overcoat (Endeavor) stent was developed by Medtronic
and is a cobalt-based alloy stent coated with ABT578 (zotarolimus) and a phosphorylcholine
polymer. It was approved for use in Europe in 2005. In the US, it has been through the Phase III
trial, where the 2-yr data indicated fewer major adverse clinical events relative to the Cypher®
(sirolimus-eluting) stent [2]. It is worth mentioning that Endeavor II [3] and early Endeavor III
[1] clinical trial data indicated less efficacy for the Endeavor stent (compared to BMS in
Endeavor II at 9 months, and to Cypher in Endeavor III at 8 and 9 months), as measured by late
lumen loss, binary restenosis, and target lesion revascularization.
The Overcoat stent (ZoMaxx) was developed by Abbott and is a stainless steel and tantalum-
based stent, zotarolimus-eluting with phosphorylcholine as a carrier, and a biologically inert
Pharmacoat. A 9-month clinical trial data (ZoMaxx I) indicated late loss and restenosis that
significantly favored the Taxus® stent, that was used as a "gold standard" for comparison, and
further stent development was discontinued. A comparison of the 9-month ZoMaxx I data with
the 9-month Endeavor III data indicates that the ZoMaxx stent faired slightly worse than the
Endeavor stent, in terms of late lumen loss, binary restenosis, and TLR. However, the decision
to discontinue further development of the ZoMaxx stent may not have been driven by these
clinical data alone, but possibly by a strategic decision to focus on a more promising product (ex,
Xience® V).
Considering the clinical data for the Endeavor and ZoMaxx stents only, one may conclude that
the No-Overcoat stent with a faster release profile, and a lower peak and total drug deposition
faired better. However, that would be an incomplete conclusion because drug deposition profiles
in a diseased state are not known and could be different from those obtained in a healthy state of
a rabbit. One additional note is in order regarding translating insights from an animal model into
a human trial. The human data is usually collected at later times points (ex, 2yrs) than the animal
data (ex, 1-6 months). Over a prolonged time in humans, a remodeling of the vessel can occur
that can't be appreciated in a short-term animal model. The question then arises as to what
would be the right animal model, and that is partly addressed in Chapter 4.
It has been shown that drugs with different physicochemical properties deposited into healthy
tissues at different rates and to a different extent (Chapter 2). Now it becomes important to know
how drugs deposit into vessels having a different pathological state. We hypothesized that the
same drug will deposit differently into tissues of different structural composition, ex, differently
in healthy and diseased arteries. Addressing this hypothesis to of utmost importance in
discerning the mechanisms of drug deposition in diseased arteries stented in the clinic, and we
pursue it further in the following chapter.
Figure 38 Surgical Procedure of Stent Implantation Into the Rabbit Iliac Artery
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Figure 40 Two-compartmental model for drug release from stents and its deposition into the
surrounding arterial tissue.
Figure 41 Drug Release from Stents
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Figure 43 Model Solution for C (i.e., tissue drug conc.)
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CHAPTER 5: Summary and Future Work
5.1 Thesis Summary
At present, 4 years after the FDA approval of the Cypher (Sirolimus eluting) stent and 3 years
after approval of the Taxus (paclitaxel eluting) stent there is a continuing need for further
mechanistic studies of how these drugs interact with and affect, pharmacokinetically and
-biologically, the stented arterial wall. The interest in mechanistic studies is persisting because
evidence for a possibility of a substantially higher risk of stent thrombosis in DES, relative to
BMS, remains inconclusive.
To fill in the void, i.e., to extend the mechanistic knowledge of drug - arterial wall interactions
this thesis has sought to address, to a certain extent, each one of the three factors necessary for a
successful DES:
1. a drug and its physicochemical properties (size, shape, hydrophobicity, etc.),
2. the state of the arterial tissue and its ability to retain the drug at an optimal concentration for a
desired biologic effect,
3. a stent delivery platform, which can be defined in terms of its bare metal stent parameters
(shape, length, material, flexibility, etc.) and drug/coating parameters (drug concentration,
polymer porosity, release profile, etc.).
In Chapter 2, we showed that drug hydrophobicity affected drug pharmacokinetics in the arterial
tissue. Hydrophobic drugs, as opposed to hydrophilic drugs, saturated the tissue slower, reached
tissue equilibrium later and deposited at significantly higher concentrations than what was
present in the bulk solution. These observations were likely due to the fact that hydrophobic
drugs, on their diffusion through the tissue, encounter general and specific binding sites to which
they bind and that delay drug transport through the tissue. Further, hydrophobic drugs eluted out
of the tissue slower and remained in the tissue at some residual concentrations that were not seen
with hydrophilic drugs. Binding sites, specific more likely than general, were thought to be
responsible for residual concentrations, as they could capture drugs to prevent them from freely
eluting out of the tissue. Lastly, hydrophobic drugs, as opposed to hydrophilic dextran,
distributed across the arterial wall in nonlinear patterns that likely tracked the non-uniform
distribution of specific and general binding sites.
In Chapter 3, we learned that paclitaxel deposition was reduced to a greater extent than
deposition of rapamycin (sirolimus) or its analogue, everolimus, in atherosclerotic lesions in the
human and rabbit. In addition, paclitaxel distribution in the rabbit model showed an altered
pattern with disease, something not appreciated for everolimus. Next, we learned that diseased
arteries in rabbits fed a high fat diet had higher levels of lipid and collagen, and also non-drug
binding areas of necrosis and calcification, while they had lower levels of tubulin and elastin
than injured arteries. At the same time, they had lower levels of paclitaxel, presumably because
lower-affinity binding elements, lipid and collagen, as well as areas of necrosis and calcification
displaced the higher-affinity binding elements, tubulin and elastin. The implication of these
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findings is that drugs will partition into different lesions dependent upon lesion's structural
composition.
In Chapter 4, we showed the stent platform with an additional polymer coating, the "overcoat"
stent, had a slower release kinetics in-vivo than the "no-overcoat" stent. The slower release
kinetics resulted in higher arterial drug deposition over 28days. The implication of these
findings is that drug release kinetics from a stent need to be matched with the tissue uptake
capabilities, for an optimal drug deposition. Besides drug pharmacokinetics, biologic effect
would need to be considered, as higher deposition doesn't necessarily mean more effective
treatment (there is an optimal deposition between low and potentially ineffective, and high and
potentially toxic deposition). A two-compartment mathematical fit to the data indicated a small
(8%) difference in drug elimination from the tissue between the cases, and a modest difference in
the percent drug absorbed by the tissue from the stent (10% for the "no-overcoat" and 20% for
the "overcoat" stents). Further refinement of the mathematical description of this in vivo
experiment could create a model with predictive capabilities - to forecast what could happen
with drug deposition if a different drug, tissues with different properties, or stent with different
release kinetics are considered.
The above outlined findings are anticipated to lead to better understanding of drug transport
mechanisms in healthy and atherogenic arterial tissues, as well as to meaningful disease models
for endovascular device design and evaluation.
5.2 Future Work
There are several questions that this thesis has raised and that are of interest to be pursued
further.
5.2.1 Drug Transport in Healthy Arteries
Drug deposition as a function of Drug Bulk concentration
In Chapter 2, an experiment of drug uptake with increasing bulk concentration eluded to a
possibility that tissue uptake capacity may vary with the bulk concentration (Figure 5). The
experiment was conducted using radiolabeled and mixtures of radiolabeled and non-labeled
paclitaxel in PBS, at room temperature. Paclitaxel bulk concentrations ranged from 10-9M to
10-5M, and drug uptake increased from 10-9M to 10-8M and then decreased from 10-8M to 10-
5M. The increase in drug uptake with bulk concentration can be explained by a general model
proposed by Lovich et al. (Figure 45, [2]). According to the model, tissue bound concentration
would increase at low concentration and reach a plateau. The soluble tissue concentration is
non-saturable and would linearly increase with the bulk concentration. The total tissue
concentration, being the sum of the bound and free concentration, would increase with the bulk
concentration. What was measured in the experiment in Chapter 2 was effectively the total
tissue concentration, more specifically, the ratio of the total to bulk concentration, and it's
increase with the bulk concentration is logical. However, it is not clear why drug uptake would
decrease at the concentrations from 10-8M to 10-5M. These results, therefore, warrant further
investigation at room temperature and at 37C. The temperature may be an important factor for
this experiment, as paclitaxel binds to microtubules, and microtubule stability is temperature
dependent (close to total assembly at the body temperature, 37C, and no assembly below 10C
[3]). Further, it would be interesting to investigate if a decline in drug uptake occurs with other
drugs, like everolimus or rapamycin.
5.2.2 Drug Transport in Diseased Arteries
In Chapter 3, we showed that diseased arteries had altered ultrastructure (increase in lipid,
collagen, and decrease in tubulin and elastin) and also a decrease in drug deposition, relative to
injured arteries.
Correlations between ultrastructural changes and changes in drug deposition
One of the goals in Chapter 3 was to correlate changes in drug deposition with ultrastructural
changes of disease. The concentration of a given ultrastructural element (tubulin, lipid, collagen,
and elastin) or drug in each tunica layer (neointima, media, or adventitia) could be measured by
morphometry, whereas the result can be expressed as the percent pixel area that is of a given
color. This was the method that was used to generate graphs and deduce correlations in Chapter
3, where either the total compartment was used for measurements (in the case of tubulin) or 3
sampling areas within each compartment (in the case of lipid, collagen, elastin, and drug). A
more accurate way to correlate drug presence with ultrastructural elements is to obtain
histograms of drug images and ultrastructure images (for each tunica layer), and to develop
correlations between histograms.
In an image processing context, the histogram is a graph of pixel intensity frequencies. The x-
axis ranges from 0 (typically taken to be black) to 255 (taken to be white). The y-axis represents
the number of pixels of a given intensity. Each pixel from a color image is a combination of tree
values, red, green, and blue. Therefore, a histogram of a color image can be expressed in terms
of any of these three colors, or in terms of their combination. One such combination is
luminosity - in Adobe Photoshop 4.0, where morphometry was done, luminosity is calculated as:
Luminosity = 0.299 (Red) + 0.587(Green) + 0.114(Blue). In Adobe 4.0, however, only graph
images could be obtained (Figure 46), and histogram data could not be exported easily for
analysis. There were two options for further analysis. One was using MetaMorph 6.01 software
(on the fluorescent microscope) and the other option was using Matlab.
a. MetaMorph Software
After an image is opened, and a particular tunica layer selected, the histogram data can be
exported into Excel for each of the three colors. Luminosity data can be calculated as an RGB
combination (Figure 47). The details on this protocol are given in the Appendix.
b. Matlab Software
The data from the Adobe Photoshop, after manipulation by Dr. Vijaya Kolachalama in our
laboratory, is exported into Matlab. Correlation coefficients between the drug and the
ultrastructural elements are being obtained at this time. Not all correlations may yield high
correlation coefficients, and some coefficients may not be meaningful - that would be the case
where there is no significant amount of an ultrastructural element, or where the histogram
quantification technique may not have been adequate. The latter may have been the case for
elastin, where there was background staining and histogram values may not reflect elastin
staining alone.
Drug deposition into isolated components
The work in Chapter 3 has given us insights into how different structural elements, like lipid,
tubulin, elastin, or collagen, affect drug uptake. As these elements all simultaneously affect drug
uptake, and possibly in opposite directions, the correlations between the drug and an element
presence may not have been made apparent. Therefore it would be instructive to measure drug
uptake into isolated components. For example, uptake into tubulin could be assessed from drug
uptake into smooth muscle cells in culture. Elastin and collagen may be isolated from an artery
and used to test drug uptake. Lipid isolation could be tricky and a suitable lipid form is to be
found in order to test drug uptake. Some possibilities include cholesterol and cholesterol ester
solutions, lipid enriched smooth muscle cells, or lipid isolated from a diseased human abdominal
aorta. In each one of these scenarios, for each one of the components, it will be important to
strive, as much as possible, not to alter component properties by isolating them from the arterial
environment.
Drug deposition vs. ultrastructure in other arterial states
Ultrastructure may play role in drug deposition in any setting. For example, dextran showed a
differential deposition between calf abdominal aorta, thoracic aorta, and carotid artery [1]. It is
conceivable that hydrophobic drugs like paclitaxel may exhibit differential deposition in
different vascular beds, in native state, dependent upon ultrastructural composition of the
vasculature. More specifically, elastic arteries like aorta (that contain many elastic laminae
within the media) may lead to a different drug deposition levels than muscular arteries like
coronary arteries (where there are not as many elastic laminae within the media).
Because of the necrotic and calcific nature of the 5-month rabbit model used in Chapter 3, it may
be informative to reproduce the studies done in that model in the 1-month rabbit model. That
may give a more clear dependence of drug uptake upon ultrastructure. The advantages of the 1-
month rabbit model (relative to the 5-month model) are that it likely contains greater amounts of
tubulin and elastin, about the same or greater amounts of lipid, and about the same or lower
amounts of collagen. These studies would be further informative if conducted in diabetic rat or
pig arteries.
Different or multiple drugs
The studies of what happens to a drug in a diseased state were conducted using Paclitaxel. It
remains of interest whether changing ultrastructure in disease could affect deposition or
distribution of Sirolimus or Everolimus. So far, investigation with these drugs has been hindered
by the lack of available techniques - neither drug has been known to have a fluorescent
conjugate and the radiolabeled conjugates are unstable. Therefore, any further studies with these
drugs would hinge on having the appropriate conjugates.
Competitive effects
Lastly, one may consider investigating competitive effects of different drugs (ex, paclitaxel and
everolimus or rapamycin) in diseased tissues. The motivation behind this work comes from the
question whether there are any contraindications to opposing two stents with two different drugs.
Immunohistochemistry for Tubulin and FKBP-12 (in Frozen Sections)
If the work with everolimus or rapamycin is to be pursued, a more sensitive technique may be
needed for tracking FKBP-12 than the one used in this work. As is, the FKBP-12 staining
sections are faint. An improved technique may involve staining frozen rather than paraffin
sections, or using another antibody in case of non-rabbit tissues (for rabbit tissues, there was only
one antibody available as of July 2006).
Staining frozen sections would have a great advantage in the case of Tubulin, because FITC-
paclitaxel and lipid are viewed in frozen sections and other ultrastructural elements (collagen and
elastin) can also be viewed in frozen sections. If Tubulin staining could also be done in frozen
section, the possibility of correlating all elements with the drug would be complete. As is,
tubulin was detected by immunohistochemical staining of paraffin sections, because staining of
frozen sections proved unsuccessful . However, there are two possibilities for making staining of
frozen sections work:
1. One possibility is to use an improved tubulin staining method available from Covance
Research and included in the Appendix. This method is thought to be an improvement from
previous methods because of an additional step that allows for tissue section incubation in
methanol, facilitating antibody penetration into the tissue.
2. The other possibility is to use immunofluorescence, i.e., stain for Tubulin using a
fluorescent antibody. A preliminary result of this staining shows b-tubulin in red and FITC-
Paclitaxel in green (Figure 48). The correct color combination needs to be used during image
analysis (MetaMorph software) in order to optimally show colocalization of drug with tubulin.
Also, two experimental controls need to be used and be confirmed negative (only one was used
when the preliminary image was generated): (a) tissue incubated in the primary antibody, and (b)
tissue incubated in the secondary antibody. The protocol for this experiment is given in the
Appendix.
5.2.3 Three-compartment modeling of in vivo data
To capture the experimental data more accurately and create a model with potential predictive
capabilities a 3-compartment model has been proposed (Figure 49). The new compartment,
compared to a model used in Chapter 4, is the blood compartment. Within the tissue, the drug
can still exist as free or bound, and either form can transform into the other as described by a
forward (kf) and reverse (kr) binding constant. Drug transport between stent and tissue, stent and
blood, and tissue and blood is described by mass transfer coefficient, kst, ksb, ktb.
Governing equation
The governing mass-transfer equations for this system are:
dCsVs dt =- kasb (Cs- Cb) -ktast(Cs-Ct) Equation 5.1
vtdCf dB)=C Equation 5.2
Vt ( dt d =kstast (Cs - Cf)-kbtabt(Cf-Cb)
with an assumption of steady state binding,
dB
dt Equation 5.3
The initial conditions are:
1. an initial specific drug concentration on the stent, and Cs(t = 0)= Cs Equation 5.4
2. initially,, no free drug is present in the tissue. Cf (t = 0)=0 Equation 5.5
Parameter estimation
Mass transfer coefficients
ksb, the mass transfer coefficient between the stent and the blood can be experimentally
estimated in a flow cell that contains a drug-coated stent and blood, but no tissue.
ktb, the mass transfer coefficient between the tissue and the blood can be experimentally
measured through kinetics of drug uptake into the tissue, for a non-binding drug (that has a
similar molecular weight as a drug in question),
kst, the mass transfer coefficient between the stent and the tissue, can be experimentally
estimated from a setup where a stent is apposed against the tissue - for example, coating a tube
with a drug and coating and embedding it into an artery -> short time points will yield this
parameter.
Binding parameters
Binding parameters, Bmax and Kd, can be estimated as outlined by Lovich et al., Figure 45.
Model predictive capabilities
After obtaining the solution for the model, given a good agreement with the data, the model
parameters can be varied to show which parameters are the most sensitive, i.e., which parameters
are the most important for drug deposition. The model can be used to investigate what happens
to drug deposition for different drugs, disease states, or stent release kinetics. The value of doing
this exercise is obtaining data relatively quickly and cost-effectively relative to in vivo animal
experiments.
K Bulk Phase Concentration
Figure 45 Model of drug distribution through tissues at equilibrium (from Lovich et al.)
The total tissue concentration is the sum of the bound and the soluble fractions. The soluble
concentration increases linearly with external or bulk concentration, whereas the bound fraction
saturates.
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Figure 46 Adobe Photoshop Histogram of a histology image.
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Figure 47 Luminosity calculated from MetaMorph RGB values.










Figure 49 A 3-compartmental model proposed to describe deposition of a drug released from a
stent and into a neighboring arterial tissue.
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Figure 50 A b-tubulin image of a diseased artery, and two linescanes of pixel intensities along
the line across the artery.
The top linescan is a MetaMorph-obtained image. The bottom linescan has been reconstructed
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APPENDICES
Appendix 1: Quantifying a Radiolabeled Compound in the Bulk
Arterial Tissue
Purpose: The purpose of this procedure is to establish the equilibrium time point for the uptake of a
model compound (10 kDa Dextran) by the arterial tissue.
Because of the high extent of labeling of Dextran (high radioactivity per low quantity of drug)
this procedure likely can't be used to establish the saturation limit of Dextran in the tissue (higher
concentrations of dextran would be needed, requiring a mixture of hot and cold dextran).
1. Prepare the bulk solution of the radiolabeled compound, in which the arterial samples will be
incubated'. The volume needed will be = N (no. tissue samples/time point) x (number of time
points) x lml (volume in each c-tube).
2. Place Iml of the bulk solution into each c-tube (centrifuge tube).
3. Clean the artery of excess fat and fascia (soon after animal sacrifice).
4. Section into segments, so the segments can fit into 1.5ml c-tubes.
5. Keep the samples under PBS as long as practical.
6. Take out each tissue sample, blot dry on a paper towel, weigh, and drop into a c-tube.
7. Place in a 37C-oven (or at room temperature) for a duration of a time point (ex, lh, 2h, 4h, etc).
8. Once a time point has been reached, take the sample out of the oven, then out of a c-tube, blot dry
on a paper towel, and place in a scintillation vial.
9. Add 1-ml of Solvable.
10. Keep at 55-60C until the tissue piece is no longer visible (-14-24 hrs, depending on the species
and the sample size).
11. Cool the solution.
12. Add 10ml of the Scintillation cocktail.
13. Wait for at least lhr.
14. Run the samples on LSC.
15. Plot data as amount drug/weight tissue.
16. Before the start of the experiment take two samples of the bulk fluid, 100ul each, and place in two
scintillation vials. Add 10ml of cocktail and count using LSC.
17. At the end of each time point, besides taking the tissue sample, take a 100ul sample of the bulk
fluid, add 10ml cocktail, mix, and count using LSC.
Steps 16 and 17 will help determine if there is any appreciable change of drug concentration in the
bulk fluid during the experiment.
1 For dextran (MW=10 kDa, 2.2 mCi/mmol), I used 0.1 uCi/ml as the bulk solution, and Iml of that solution per
tissue slice (smaller volume may be used provided that the bulk concentration does not change appreciably during
the expeirment, so that the constant boundry condition can be used).
Appendix 2: Cryosectioning and Quantifying a Radiolabeled
Compound
(Materials needed for the experiment are underlined)
Tissue freezing
1. Label a glass slide (top middle edge) with the sample number (use thin marker, which won't
colle off).
2. Take a tissue sample out of the drug solution, drop in a vial of water, and blot dry.
3. Place the sample on the glass slide, adventitial side down.
4. Place a drop of OCT over the tissue sample.
5. Place glass cover slips (22x22mm or 18x1 8mm) on each side of the glass slide
(3 on each side - Rabbit AA; 6 on each side - Human AA).2
6. Place another glass slide on top (carefully, so that glass slips don't fall out).
7. Place a small binder clip on each end of the slide pair (test clips for -uniform grip).
8. Measure the dimensions of the tissue sample using calipers.
9. Immerse the slide pair into liquid nitrogen until OCT (and tissue) freezes (i.e.. N2 bubbling
subsidcs ).
10. Wrap each slide pair into parafilm or serena wrap.
11. Place slide pairs in a blue container (label - exp.date, initials) and into -20C freezer.
Tissue sectioning
Prior to starting this procedure label the glass scintillation vials.
1. Take a plastic mold and fill it half way with OCT. Leave it at -20C to freeze.
2. Once OCT is frozen, peel off the mold, and smooth the biggest side by briefly rubbing on the
cryostat glass cover.
3. Quickly place a blob of OCT onto a cryocassette, press the mold onto it until it's glued frozen.
4. Place the cryocassette with the mold onto the specimen head.
5. Next, take a knife out of the knife box and wipe clean with ethanol.
6. Place the knife into the knife holder.
7. Orient the cassette and the mold, so the mold is fairly parallel to the knife blade.
8. Cut a few 20um sections from the mold.
9. Take the glass slide out of the freezer and place it into the cryostat (-20C).
10. Take a glass slide with the tissue sample and rub over the adventitial slide, so that it warms up
and detaches. Carefully collect the glass cover slips.
11. You are left with the intimal slide and the tissue sample. 3
12. Press the tissue sample onto the mold and carefully slide the intimal slide off.4
13. Now the tissue sample is on the mold (with the intimal side facing you). Put a black dot on the
tissue sample using a marker.
14. Add OCT all around the sample and over it (no empty space at the bottom) and let freeze.
15. Retract the specimen head.
16. Section the mold until the point where black dot is visible. Now, you are ready to start collecting
the samples. Check that sections are 10um thick.
17. Collect two 10um sections per glass vial.
2 Or less cover slips - artery needs to be very well pressed, so that sections come out square.
3 Don't let the tissue thaw a lot or deform during transfer (tricky) - when you press it againt the mold (next step) it
needs to retain its pressed and uniform shape as much as possible (so the sections come out square).
4 Tissue location is best - top half of the chuck.
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18. Continue sectioning until the tissue sample doesn't look rectangular.
Drug Quantification:
a. Add 1-ml of Solvable to each glass vial.
b. Cap vials well, place into smaller trays, and then into the vacuum oven (50-55C) overnight.
c. The next day, take the vials out, let cool, and add about 8ml scintillation cocktail to each
vial (Hionic Fluor or Ultima Gold).
d. Mix each vial by shaking until the solution is clear.
e. Run through LSC (run background samples first) using the H3 or C14 protocol.
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Appendix 3: Preparation of FITC-labeled PXL Solution for Tissue
Incubation
"Oregon Green 4'88 paclitaxel has been used in the past for live-cell tubulin labeling. MP now offers
Tubulin Tracker Green, and acetylated version of Oregon Green 488 paclitaxel which is more soluble and
cell-permeant, allowing more uniform and consistent cell labeling, superior selectivity for polymerized
tubulin in live cells, and increased ease of use."
Tubulin Tracker Green Reagent
(for live-cell tubulin labeling, Oregon Green 488 Taxol, bis-acetate)
Storage and Handling
1. TubulinTracker Green reagent is provided as a set of two components:
a. TubulinTracker Green reagent (Component A, MW 1403), 100ug of lyophilized material
b. Pluronic F-127 20% solution in DMSO (Component B), ImL, a solubilizing agent for
making stock solutions and facilitating cell loading.
2. The products should be stored desiccated and protected from light at • -20C.
3. Vials should be allowed to warm to room temperature before opening.
Experimental Protocol
Optimal labeling conditions for each cell type should be determined empirically.
For best results, solutions that contain Pluronic F-127 should always be well vortexed before use.
Reagent Preparation
Prepare 1 mM stock solution. Dissolve the contents of the vial
of TubulinTracker-" Green reaeent (Component A) nm 71 LL of
anhydrous DMSO to make a 1 mM stock solution. This solution
should be diided Into aliquots and stored at s-20"C. ThIs stock
solution should be stable for at least three months when stored
at <-20C. There should be sufficient 1 nLmM stock solution for
approximately 280 assays usine 1 mL per assay at a final concen-
tration of 250 rNi.
Prepare 500 •MI intermediate stock solution. Vortex the Comp-
ponent B vial. Add an equal vo'ume of 20% Phlronic F-127 in
DMSO (Component B. vortexed) to a thawed aliquot of 1 mM
TubuhnTracker T" Green reagent stock (prepared above) to make
a 500 lpM intermediate stock solution. Using Pluromc ensures
good solubilitv of the TubulinTracker T Green compound- Tihs
500 pM inteimediate stock solution should be stable for 14 days
when stored at :ý-200 C.
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Cell Preparation and Slalnlng
1.1 Prepare fmal staining solution. Vortex then dilute the
500 J1~i intemlediate stock solution prepared above into HBSS/
Cal~fti (Gibco #14025-092) or other suitable buffer. Recom-
mended concentrations ranee between 50-250 0.\·1 for most cell
types. Use only a freshly made solution at 37cC.
1.2 Stain cells. Apply a sufficient amount of the final staininc
solution to cover cells adherincto coverslip(s). Incubate for
30 minutes at 37°C/5% CO:.
1.3 Rinse and view cells. Remove stainincsolution, rinse cells
three times in buffer at 37:JC. and view in buffer. NOTE: Sam-
ples should be viewed immediately after staining, as staining




Tissue Incubation if FITC-Iabe/ed PXL, Freezing, and
All steps - protect from light at all times.
Step Description Material quantities Mat. Duration & Timing
(materials underlined - order; quant. other
hardware in italics - signup) conditions. Tue,0829
to=1l:30a
1-1. Obtain tissue samples (rabbit AA). 2 samples (rings) x 45min or
3 solutions longer
1-2. Prepare the incubating solutions: 2ml -2hr
PBS (for neg.ctrl.), Oregon Green for each solution. prep time
488 Paclitaxel in PBS, and ORorTTconc
Tubulin Tracker Green in PBS. -10-6M
1-3. Incubate tissue samples as follows: Iml bath volume 48hrs, RT
one in "OR", one in "TT", and one for each sample. (or 37)
in the "blank solution" (neg.ctrl., dark,
to assess autofluorescence). shake (speed
2)5.
1-4a. At the end of the incubation period N2: full bucket 15sec
(with lights off), take each tissue Iso-P: -50ml snap freeze
sample out of the solution, place in OCT: from a bottle of tissue in
OCT and snap freeze in N2. iso-P;
Alternatively, take a tissue sample total TBD.
and snap freeze in N2-cooled iso-
£, place in a mold with OCT, and
freeze rapidly in N2 (or slowly in
the crvotome chamber).
1-4b. Third option: freeze sample in N2-cooled iso-Po Place sample into -20C chamber for 30min (to
warm up to -20C, for best sectioning). Put little OCT onto a cool chuck and the sample on it.
Add OCT around the sample (w/o OCT, can't get arterial sections onto a slide). Problem - artery
lumen doesn't get filled, the section shape is not circular ('Possible artifacts or folding'
1-5. Store the tissues at -80
-
(indefinitely) and let them warm
up to -20 (for -lhr) before
sectioning.
1-6. Section the frozen tissue sample Glass slides -lhr-2hrs
10um (or 15um) thick6• Place 2-3 (Super Frost plus)
sections on a glass slide. Repeat
with the other two samples.
5 Mc tubes laid horizontal- better shaking, but there is a potential risk of getting the sample onto the cap and not
back into the solution.
6 8um was done on the first try (0816), but that was too thin to preserve the tissue structure. 20um is too




Ci Vi = Cf Vf-) Ci/Cf = Vf/Vi = 16/4 = 4/ 1 - Vi = 12ml, Vf = 48ml (36ml water added)
7 PBS/glycerol (50/50) could be used as a mounting medium, if nuclei are not to be visualized.
8 After coverslipping, be careful with the slide. The coverslip is not glued to the slide by the DAPI medium, but
may shift, damaging the sections.
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1-7. Fix the slides in para-formaldehyde' 50ml for 1-5 slides; 10min,
(1Coplin jar, fixative, ice bucket, 250ml for 6-12 ice-cold.
ice). slides.
1-8. PBS rinse (incubation) 1min (or
longer)
1-9. Take each slide out, wipe excess 1 small drop of Note: right after coverslipping, put
water around sections, apply the medium per section the slide against the dim light and
Vectashield mounting medium with check for air bubbles on sections.
DAPI (stains the nuclei)7, and
coverslip8.
1.10. In dark, take slides to the F. scope
and visualize.
Appendix 5: Sample preparation for Histology
Fixation
(this protocol adopted from a histology text; time duration in steps (1) and (4) was 18-24hrs in all
experiments)
1. Fix fresh tissue block in formalin at 4C for 18hrs.
2. Rinse in running tap water, or for a short time in distilled water if the tissue fragment is small or
fragile, ex., injejunal biopsy.
3. Blot dry.
4. Place tissue in 30% sucrose solution (ex, 60g sucrose in 200ml DI-water) at 4C for 18hrs, or less
with small fragments.
5. Blot dry.
6. Embed into OCT (OCT placed into a mold).
7. Freeze by placing the mold in the cryostat chamber (moderate slow freezing to cryostat
temperature).
Following fixation, the block is frozen slowly to avoid damage caused by the rapid expansion of ice
within the tissue. Freezing the block by standing it in the cryostat cabinet gives acceptable results for the
majority of fixed tissue. The length of time required for this procedure means that it is of limited value
for diagnostic purposes.
Sample cutting
1. Mount frozen blocks onto a block holder.
2. Cut sections at lOum (use a brush if necessary to keep the sections flat),
3. Collect sections onto a slide (that is kept outside of the cryostat chamber, at room temperature).
Storage
1. Stain sections right away, or place slides in a plastic ziplock bag with drierite in a freezer (-20C)
overnight.
2. Upon taking slides out of the freezer let them equilibrate to room temperature before staining.
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Appendix 6: Oil-Red-O staining
Oil-Red-O (ORO) in propylene glycol
(this protocol adopted from a histology text)
Solution
1. Dissolve 0.7g of ORO in 100ml propylene glycol. Add a small amount at a time with stirring.
2. Heat to 100C (not over 110C) for a few minutes, stirring constantly. Do not exceed 110C.
3. Filter through Whatman no.2 filter paper. (Cool to room temperature and filter through fritted
glass filter of medium porosity with suction.)
4. Store in the oven at 60C and stain will keep almost indefinitely. If precipitate forms in the oil-
red-O, remove it by skimming the top with a piece of thin paper.
Technique
1. Cut frozen sections at 10um and place in distilled water.
2. Drain water off sections and place in 100% propylene glycol for 5 minutes. Agitate with a glass
rod to be sure of complete dehydration. Do not carry any water over into the ORO.
3. Place in the oven in ORO (which has been kept in the oven at 60C) for 15min. Agitate
occasionally. (A test slide was previously done for 7min, which was too short for adequate
staining).
4. Place in 85% propylene glycol for 3 minutes, stirring section gently with a glass rod.
5. Place in a small dish of distilled water to prevent tearing of the section.
6. Transfer to a large dish of distilled water.
7. Counterstain in Mayer's hematoxylin (diluted two parts of distilled water to one part
hematoxylin) for 2minutes.
8. Blue in tap water.





Appendix 7: IHC (Immunohistochemistry) Staining Preparation
Immunostaining Method In Rabbit tissues using DAKO Target Retrieval and En Vision+ System,
Peroxidase (DAB) Immunostaining Detection Kit
1. Schedule the staining with Philip 4-5 days ahead of time to make sure that he or Gee would be
around. Check the availability of all reagents (specified by the autostainer). If needed order
more.
2. Choose the Ab concentrations9: Look at the Ab Spec Sheet, and select the recommended
concentration along with one or two higher and one or two lower concentrations, for a total of 4
titer concentrations (examples, 1:10, 1:20, 1:50, 1:100, 1:200/1:250, 1:500, 1:000, and 1:2000).
3. Determine the no. of slides to be stained:
no of slides = no of exp. groups (1 slide/group) x (no of concentrations from step 1, ex., 4) + 2
(neg.ctrl. 1 = Ab diluent, neg. ctrl. 2 = mIgG'O).
4. Print the slide labels (see end of this document for details), and label the blank slides.
5. Prepare the slides - cut the specimen and place the sections on slides:
a. Paraffin-embedded specimen: speak with Philip at least 2days before the staining and
ask him about having the specimen cut (5-6um thick sections).
b. Frozen specimen: cutyour own sections; see "Histo-Sampling to Sectioning.doc"
6. Next - see "IHC Protocol-DAKO.. .doc", Autostainer Setup, to determine the volumes of
reagents.
7. If all reagents are available proceed with the staining.
9 If the working Ab concentration is already known choose that concentration and skip the rest of step 1.
0o mlgG = mouse IgG, used for primary mouse antibodies.
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Appendix 8: IHC (Immunohistochemistry) Staining Protocol
Immunostaining Method/or Rabbit tissues using DAKO Target Retrieval, EnVision+ System
(peroxidase (DAB) immunostaining detection kit), and Mouse Monoclonal Antibodies
MATERIALS & EQUIPMENT (writing in blue - from the 56 lab):
EnVision+ System: HRP (DAB) Immunostaining Detection Kit (DAKO Co., K4007)
DAKO Antibody Diluent with background reducing components (Dako, Cat.#S3022)
Ab's (mouse monoclonal), keep on ice if out of the fridge
. Mouse IgG (negative control)
Dako Wash buffer, lOx (Dako, Cat.# S3006)
DAKO Target/Antigen Retrieval Solution (lOx, Dako Cat.# S1699)
Mayer's Hematoxylin (Sigma-Aldrich); Ethanols (70%, 95%, 100%); Xylenes
Distilled water (d H20); Tap water (tap H20)
Cytoseal XYL Mounting media (xylene based), or Aqueous mounting media (if no dehydration at the
end)
24 x 50 mm Coverslips; Slide flap
Pipets and tips; 15ml- Falcon tube (can be used to hold Diluent, so thefluid level is visible).
Razor blade (to cut Parafilm); Tweezers (to transfer slides between containers)
2 Metal staining containers + 1 metal rack with handle
1 250 mL Tissue-Tek plastic staining containers + 1 gray slide rack
Reagent tubes for autostainer + tube rack
For antigen retrieval: tweezers, one insulating (orange glove), pressure cooker, Timer
Shandon Varistain XY Autostainer, plastic pipetor
NOTES:
All staining performed at room temperature unless noted.
Allow solutions and kits to thaw up to room temperature before use.
TIME COMMITMENT (8-12 slides, paraffin sections, 2x30min Ab incubation):
Preparation for the staining run (starting with slides with paraffin sections): -4hrs
Autostaining: -2hrs
Total: -8.5hrs
PARAFFIN vs. FROZEN SECTIONS:
a. Paraffin sections: make sure that deparaffinizing and antigen retrieval are done just before the
run (follow all steps below).
b. Frozen sections (previously fixed):
i. If slides come from the freezer, let them equilibrate to room temp in a desiccant bag,
then rehydrate (in the kit buffer) for at least 1/2-1hrll • Place in the autostainer, keeping
the slides moist at all times, and start the run.
11. If slides freshly prepared, air dry, then rehydrate (in the kit buffer) for at least 1/2-1hrl •
Place in the autostainer, keeping the slides moist at all times, and start the run.
CALCULATIONS: 250ml x 0.70 = 175ml (250ml x 0.30 = 75ml)
250ml x 0.95 = 237.5ml (250ml x 0.05 = 12.5ml)
II An important factor for staining to tum out well.
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Do this step before
ordering Ab's or the
Staining Kit






"DC Autostainer Plus" icon -> open (login gee, pass dako):
Program -> File option: find a file by a previous date, make required
changes to it (left or right mouse select).
Print -> slide labels (enter slide no's, ex. 1-1612), reagent labels (all),
program grid.
Next -> print reagent volumes
Next -> slide order
Next -> Save as "current date"
Next -> Set start time -> gives info on buffer and di-water volumes.
Prepare both solutions and fill the containers.
Check the waste containers: thin clear tube goes into non-hazardous
waste; big clear tube and small black tube go into hazardous waste.
The stainer is ready for Step 5 (slide loading & starting the run).
The program will give the minimum volumes for the following
reagents:
a. H202 (from the kit bottle)
b. Envision' (from the kit bottle; "Labeled polymer-HRP anti-
mouse"1 3)
c. DAB (buffer from the kit bottle, plus 1 drop chromagen/ml
buffer' 4)
d. Neg ctrl - Ab diluent (from the Diluent bottle)
e. Neg ctrl - m-IgG (m-IgG and diluent)
f. Ab titer 1 (Ab and diluent)' 5
g. Ab titer 2 (Ab and diluent)
h. Ab titer 3, etc.
i. Wash buffer and DI water (for the autostainer).
* Take the reagents from the fridge, let them warm up to RT
(Wash buffer, Antigen retrieval solution, Envision Kit, Diluent).
* Write down the catalog & lot numbers for all.
Using the labels printed by the Autostainer, label the slides again
(date, titer, slide no.) and label the reagent tubes.
Prepare the Wash buffer for wash steps (3 and 5a), that are
independent of the autostainer (2x300ml).
12 Slides may already have the labels (from before sectioning). These labels (the informative lines cut out) are added
to the bottom of the first labels.
13 The big bottle is for mouse Abs, the small bottle is for rabbit Abs.
14 Ex.: for about 10ml total => 10ml buffer + 10drop chromagen (the final vol. > 10ml)
15 Example: 1:50 titer with the total volume of 800 ul means - 16ul Ab and 784ul Diluent (pipet out 800ul Diluent;
then using the same pipet withdraw 16ul of Diluent and add 16ul of the Ab).
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(add. Mat.: tweezers, 1 ins.
orange glove)
16 This is the same solution that will be used as a running buffer for the Autostainer (depends on the kit being used).
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Place the slides with paraffin sections in the oven at 60C for 20mnin.
Take the slides out (ok to cool down).
Shandon Varistain XY Autostainer (program 5):
* Review container contents (3 back R., 4 middle L., 1 front L.; 8
containers total; ends in diH20; same as solvent list below).
* Mount the rack.
* Press "Stain", enter "5" (make sure it will start with Stepl),
"Review" parameters (solvents & timing), "Complete", "Start" (total=
23min).
(1-3) 100% Xylenes - 3x3min.
(4-5) 100% ETOH - 2x3 min.
(6) 95% ETOH - 3 min.
(7) 70% ETOH -3 min.
(8) dH20 - 2 min (here, release the slide rack from the automatic arm,
and hit "Complete").
Take the slides, one by one, out of the DI water and place into 300mL c
the Wash buffer 16 for 5 min or longer.
Prepare 400ml of 1X Target Retrieval Buffer (10X solution from the
fridge, Dako # S 1699, is diluted with DI-water).
1) Place 1-1.5L of DI-water in the pressure cooker, on a Hot Plate
(turn up to 10). Place in a square metal container with 400mL of lx
Target Retrieval Solution and a cover. Pre-boil the Retrieval Solution,
i.e., wait until all boils, then place a metal rack with slides in the
Solution (pH=6.0). Cover the container, cover the cooker, and place
the regulator on the cooker lid.
2) Heat on Hot plate for 20 min. total.
3) Take Pressure cooker off of Hot plate with warm gloves and rinse
cold water on the outside of Pressure cooker to cool down in sink.
Allow the pressure lock to release, then open top lid of Pressure
Cooker and remove square metal container with slides. Allow the
container to cool for 20 min. with cover off.
5a Rinse Place in a 300 mL metal container filled with the (fresh)
lx Wash buffer (keep in the buffer until the staining
solutions and the autostainer are ready for the run).
5b Staining Reagent prep. Prepare the staining reagents in plastic tubes' 7 (see * step
on the previous page for detail).
Write down the lot numbers for the: Envision' Kit, Diluent,
and all Abs (useful if the staining does or doesn't work).
Prepare the wash buffer for the autostainer. Mix the 10X solution with
DI-water in a graduated cylinder, and pour into the jug, which is
located on the floor next to the autostainer.
Check the DI water level in the appropriate jug.
Check the buffer waste bottle (if potential overflow,
discard the contents down the sink).
5c Slide loading & Start Load the slides (slide label goes into the groove) into the
Stainer. Keep the slides moist as you load them at all
times prior to starting the run.
Check that all slides and solutions are in place.
Start the run.
Steps 6-13 - done by the Autostainer.
Starting the autostainer:
Computer screen -> "prime pump (buffer)'8 ", "prime pump (water)", start run.
Priming is usually done only for the first run in a day.
14a End OK. Save run - Yes (date ok). Print -No.
Sign off. Computer screen off.
14b Waste disposal All reagent leftovers, except the DAB - down the sink.
DAB - into a small jug below the stainer.
Regent tubes (only for H202, DAB) - reused.
The rest of the procedure - performed manually.
15 Rinse Place slides into a 250 mL container (gray slide rack) filled with dH20.
16 Counterstain Mayer's Hematoxylin - 1 minute.
17 Rinse tap H20-5 min (running rinse)
dH20 rinse (still)
Xylene-based mounting media: steps 18-24'9, OR
Aqueous-based mounting media: step 2520,21 (for ORO, or quick result with other stains).
17 Volumes slightly greater than those printed can be prepared, to account for the fact
that volumes less than lul cannot be pipetted out. At the end, mix the solutions.
18 After pressing this button wait until the prime is over (the initial message apears on the button).
19 Another technique, not in use because it forms bubbles, used "Advantage permenant mounting media: after





These solutions are in 250 ml T-Tek staining containers, in the fume
hood. They should be different from those used for deparaffinization
and should be clear (not tinted).
70% Ethanol - 1 min.
95% Ethanol - 1 min.
100% Ethanol - 1 min.
100 % Ethanol - 1 min.
Xylenes - 2 min.
Xylenes - 2 min (or longer).
Take slides out and apply a few drops of mountant media, then
coverslip with 24x50 mm coverslips.
Take each slide out of the water, wipe off excess water, and place
3drops of the Aqueous Permanent medium (Dako S 1964) over the
slide. Let dry.
20 "Aqueous Permanent Mounting Media": after "Rinse", take slides out and apply a few drops of mountant media
(3/drops per slide spread around, so that all tissue sections get covered), and let the slides dry without coverslipping.
21 The disadvantage of this medium compared to the Xylene medium/coverslipping, is in variable optical properties
over the surface of the slide (aqueous medium varies in thickness). ORO has to have this aqueous medium. Other




IHC Staining of Frozen Sections by CRP
Step 1 Cut 10 micron sections of frozen autopsyoranimal tissue and dry for 15 to45 minutes at room
temperature on gelatin coated slides.
Step 2 If the tissue has not been fixed before sectioning, hydrate with buffer, twice for 5 minutes each.
This treatment helps to remove IgG bound to blood vessels and red blood cells. We use 0.05M
Tris bufferpH 7.6,with 1.5% NaCI (1 .ST)forimmunocytochemistry. Other buffers, such as PBS,
can be used.
Step 3 If the tissue has not been fixed,fix with phosphate buffered Formrnalin or Bouin's for 15 to 30
minutes.
Step 4 Wash slides well with buffer (1 .5T):, three times for 5 minutes each or until fixative is completely
removed. Always use large volumes of wash buffer, especially after antibody incubations.
Step 5 Treat sections with 0.3% hydrogen peroxide in methanol for 30 minutes. The use of peroxide
to red uce "endogenous peroxid ase* may not be necessary but immersion of sections In cold
methanol or other alcohols is necessary for penetration of antibodies into the section to
ach ieve good staining for most antigens.
Step 6 Wash sections with buffer,three ti mesfor5 minutes each.
Step 7 Block potential non-specific binding sites in the tissue. There are several ways that we have
found useful;
1 ) Block with normal serum from an animal species different from the species origin of the
primary antibody. For example, use 3to 10% normal goat serum as a block when rabbit,
mouse orrat, but not goat, primary antibodies are used. Normal serum from the same, or
closely related, species as the primaryantitbody should not be used since even "normal"
seru m contains a nti bodi es that may be detected a nd prod uce "bac kg ro u nd " stai ni ng.
2) Block with dried nonfat milk solids (available from the grocery store). 0.5 - 1%O1 milk solids
in buffer is an excellent blocking agent and at these concentrations, should not inhibit
specific binding. The milk solids-buffer solution should be made fresh on the dayof use or
stored frozen.
The blocking step is normally done for 30 minutes.
Step 8 Remove the blocking agent by draining or vacuuming around the section.
Step 9 Applythe primary antibody. The optimal dilution foreach antibody must be determined since
using either too high or too low a concentration will result in decreased reaction. The optimal
range of antibody dilution may be influenced by the type of tissue and method of fixation.
Primary antibody incubation times can range from I hour at room temperature to overnight
incubations (or longer) at room temperature or in the cold. Antibodydilutions should be made
in bufferwith 1% normal serum.
Step 10 Wash sections with bufferthree times of 5 minutes each.
Step 11 Apply linking antibody diluted 1:100. For best results, it is advisable to determine the optimal
concentration of this antibody by using a series of dilutions. A 30 minute incubation is
recommended. When using auto psy tissue, it is advisable to use a linking antibody especially
prepared to eliminate IgGs that may cross react with human IgG (forexample catalog SMI-
5050C, Goat anti-Mouse IgG for use with mouse monoclonal primary antibodies). Antibody
should be diluted in buffer containing 1% normal serum.
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Stop 12 Wash sections with buffer three times for 5 minutes each.
Step 13 Apply the appropriate peroxidase anti-peroxidase (PAP) complex diluted 1: 100 in buffer
containing normal serum for 30 minutes. Titering the PAP will determine whetherother
dilutions may be used. Save any remaining solution for testing the diaminobenzidine
hyd rochloride(DAB -hydrogen peroxide solutio n.
Step 14 Wash in buffer three times for 5 minutes each.
Step 15 Make up DAB/hydrogen peroxide solution in .5ST with a final concentration of 0.05% DAB plus
0.01% hydrogen peroxide immediately before use. Keep cold. Do not use if the solution looks
brown. Test the DAB solution by adding a few drops to the leftover PAP
Step 16 Add DAB solution to sections and incubatefor8 minutes at room temperature. Timing is
important.
Step 17 Wash with buffer three times for 5 minutes each.
Step 18 Dehydrate with graded alcohols and xylene and coverslip sections with Perm ount.
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Appendix 10: IF (immunofluorescence) Staining for Tubulin
Purpose: Colocalization of PXL and Tubulin
If the fluorescent label is seen under microscope, on FITC-PXL saturated tissue sections,
proceed with tubulin labeling as follows (all steps in dark):
22 not formalin (to reduce autofluorescence)
23 Abb: We can also try actetone/alcohol if this doesn't work.
24 Suggested here is goat serum. Secondary Ab later is then goat anti-mouse (mouse IgG).
25 Either box or the container are wrapped in Al foil.
26 As you pipet out the solution onto the slide, be careful not to touch the sections.
27 High Ab conc. for a short period of time (trial values). In the past, 30min at 1:250 dilution gave some staining in
IHC (fr) with this antibody.
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Step Description
(materials underlined - order;





No. of Slides: total of 4. neg.ctrl.l-15um. TT-15um. TT-10um. OR-10um. OR-15um.
Section thickness (given the previous experiment, 0816): 8-20um.
** forgot to do neg.ctrl.2 (Pxl w/20 Ab, no 10 Ab)
Sectioning: Try to place the sections all in the midline (makes the blocking and staining steps easier).
2-1. After sectioning, fix slides in fixative volume: 50ml 10min
4% paraformaldehyde 2223 (on ice). 50ml
1 Coplin jar or 250mi
2-2. Rinse 3x with PBS. 3x50ml 3x50ml 3x5min
2-3more Coplin jars or 3-X250m1l
2-3. Blocking; step: 200ul per slide26  4x200ul -> 45min
Incubate in 20% goat24 serum in or I x50111 or 1.0-2.0ml
PBS I x250ml total.
in a humidified chamber (manual 0.2-0.4ml
staining box, or a tupperware serum.
container, where slides rest on 2
parallel plastic pipets and wet
paper towels 25).
2-4. Rinse 3x in PBS. 3x50ml 3x50ml 3x5min
or 3•2_50m1l
2-5. Wipe extra fluid from each slide. hph pen
Circle sections with hydrophobic -
(hph) pen.
2-6. Incubate with the primary antibody 10 Ab ex., mouse 4x300ul > 1 -hr,









For Steps 2-1 to 2-11:
Fixative vol, ml: 50ml. other:
PBS vol, ml: 3x50 + 3x50 + 4x50 = 500 ml. other:
1% BSA/PBS vol, ml: 2ml 4 5ml - 5g (0.05g BSA, 5ml PBS) other:
28 Alexa Fluor 594. Goat anti-mouse IgG, fragment. 2mg.ml. A11020, 250ul. Lot 36506A (Invitrogen/Molecular
Probes).
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2-7. Rinse 3x in PBS. 3x50ml 3x50ml 3x5min
or 3x250m1 1
2-8. Incubate in the secondary 20 Ab ex.: goat 4x300ul -> 1-hr, RT.
antibody in PBS with 1% BSA in anti-mouse, 1,400ul
a humidified chamber. ALEXA 594
labeled28. 1:200 solution:
1:200; 200ul per 7ul Ab
slide, or (alexa)+
Idrop/section) 1393ul pbs/bsa
2-9. Rinse 4x in PBS. 4x50ml 4x50ml 4x5min
or 4x250ml
2- Mount with DAPI containing "1 small drop/section" ted=8:15p
10. mounting medium and coverslip. (note: cover slip doesn't stick to the
slide)
2- Observe for the presence of
11. tubulin, Paclitaxel, and nuclei
under a fluorescent scope.
Appendix 11: Data Tables for Chapter 4
TABLE 1: Summary of ABT-578 Deposition in the Iliac Arteries (at 1 DAY)
NO No-overcoat Stents
rox dist adv dist
ug-drug/g-tiss 504 5 9 19 726 9 14 14
SE 140 1 2 8 154 3 3 5
ug-drug/g-tiss/ug-rel 8.5 0.1 0.2 0.3 10.3 0.1 0.2 0.2
SE 1.8 0.0 0.0 0.1 2.4 0.0 0.0 0.1
ug-drug/ug-rel 12.5% 0.2% 0.1% 0.1% 13.1% 0.3% 0.1% 0.1%
SE 2.6% 0.0% 0.0% 0.0% 3.2% 0.1% 0.0% 0.0%
STENT ug % ug 0/0
Ave released 69.2 69.2% 74.6 74.6%
SE 4.9 4.9% 4.7 4.7%
TABLE 2: Summary of ABT-578 Deposition in Solid Organs (at 1 DAY)
-0 brain liver kid een carotid onad heart lu intest Ave wlo carotid
ug-drugg-tiss 6.5 6.3 7.2 7.9 2.4 8.9 7.0 5.2 6.4 6.9
SE 1.2 1.6 0.5 2.2 0.6 1.2 0.6 0.3 0.7 0.4
ug-drugg-tisslug-rel 0.04 0.03 0.05 0.04 0.01 0.07 0.05 0.04 0.05 0.05
SE 0.002 0.004 0.002 0.008 0.002 0.020 0.011 0.004 0.002 0.003
ug-drug'ug-rel 0.18% 0.16% 0.19% 0.18% 0.06% 0.23% 0.21% 0.16% 0.18% 0.19%
SE 0.01% 0.02% 0.02% 0.02% 0.003% 0.08% 0.07% 0.02% 0.01% 0.01%
-NO brain liver kid carotid onad heart lu intest Ave wlo carotid
ug-drug'g-tiss 6.9 6.2 5.7 2.3 9.2 6.0 6.6 8.7 7.1
SE 1.0 1.1 0.1 0.7 0.9 0.6 0.9 1.8 0.4
ug-drugg-tisslug-rel 0.05 0.04 0.04 0.01 0.06 0.04 0.04 0.06 0.05
SE 0.007 0.011 0.003 0.003 0.010 0.007 0.004 0.012 0.386
ug-drug'ug-rel 0.19% 0.17% 0.17% 0.04% 0.19% 0.17% 0.17% 0.20% 0.18%
SE 0.03% 0.03% 0.02% 0.01% 0.02% 0.02% 0.02% 0.03% 0.01%
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TABLE 3: Summary of ABT-578 Deposition in the Iliac Arteries (at 3 DAYs)
0 (Overcoat Stents) NO (No-Overcoat Stents)
Summary artery adv prox dist artery adv prox dist
ug-drug/g-tiss 1339 25 128 195 531 13 96 89
SE 413 12 24 64 172 2 27 28
ug-drug/g-tiss/ug-
rel 31.3 0.6 2.4 4.4 5.8 0.1 1.0 1.0
SE 9.9 0.3 0.6 1.7 1.9 0.0 0.3 0.3
ug-drug/ug-rel 45.0% 1.9% 1.0% 1.3% 7.0% 0.4% 0.4% 0.4%
ir- ,rnA nA/ An A "fi In '/ AA/ A1 A / i! 1 Ain/I 









TABLE 4: Summary of ABT-578 Deposition in Solid Organs (at 3 DAYs)
Summary - brain liver kidney spleen carotid gonad heart lung intest Ave wlo carotid
ug-drug/g-tiss 6.1 4.0 2.9 15.4 50.1 6.8 5.7 4.2 10.0 6.9
SE 1.1 0.3 0.5 7.4 10.9 2.2 1.4 2.1 6.1 1.3
ug-drug/g-tiss/ug-rel 0.06 0.04 0.04 0.08 0.47 0.08 0.07 0.05 0.14 0.07
SE 0.026 0.012 0.011 0.025 0.211 0.019 0.018 0.024 0.067 0.011
ug-drug/ug-rel 0.31% 0.21% 0.18% 0.33% 0.48% 0.33% 0.29% 0.19% 0.32% 0.27%
SE 0.08% 0.06% 0.04% 0.06% 0.04% 0.03% 0.02% 0.08% 0.15% 0.03%
Summary - NO brain liver kidney spleen carotid gonad heart lung intest Ave w/o carotid
ug-drug/g-tiss 7.5 4.4 5.0 11.4 37.9 12.3 4.7 9.0 16.5 8.8
SE 1.4 0.6 2.0 7.1 11.2 6.2 0.6 2.0 4.2 1.4
ug-drug/g-tiss/ug-rel 0.04 0.02 0.03 0.06 0.21 0.07 0.03 0.05 0.09 0.05
SE 0.008 0.003 0.011 0.039 0.065 0.034 0.004 0.012 0.024 0.008
ug-drug/ug-rel 0.17% 0.10% 0.15% 0.15% 0.17% 0.21% 0.12% 0.16% 0.20% 0.16%
SE 0.03% 0.02% 0.05% 0.06% 0.05% 0.08% 0.01% 0.04% 0.07% 0.02%
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/ /.14-/n I /, III / /
Summary of ABT-578 Deposition in the Iliac Arteries (at 7 DAYs)
0 (Overcoat tents) NO (No-Overcoat Stents)
Summary artery adv prox dist artery adv prox dist
ug-drug/g-tiss 471 5 55 44 290 10 152 167
SE 121 1 12 10 38 5 60 68
ug-drug/g-tiss/ug-rel 10.9 0.1 1.1 1.0 3.2 0.1 1.6 1.8
SE 6.4 0.0 0.5 0.6 0.4 0.0 0.6 0.7














TABLE 6: Summary of ABT-578 Deposition in Solid Organs (at 7 DAYs)
0 brain liver kidney spleen carotid gonad heart lung intest Ave
ug-drug/g-tiss 4 2 2 2 15 4 2 2 6 4.1
SE 1 0 1 0 4 1 0 0 0 0.7
ug-drug/g-tiss/ug-rel 0.02 0.02 0.01 0.02 0.16 0.03 0.02 0.01 0.05 0.03
SE 0.00 0.01 0.00 0.01 0.03 0.01 0.01 0.00 0.01 0.008
ug-drug/ug-rel 0.11% 0.11% 0.09% 0.08% 0.15% 0.17% 0.12% 0.07% 0.13% 0.11%
SE 0.03% 0.02% 0.02% 0.04% 0.03% 0.07% 0.04% 0.01% 0.02% 0.01%
NO brain liver kidney spleen carotid gonad heart lung intest Ave wlo carotid
ug-drug/g-tiss 2.8 3.9 2.0 2.3 41.6 2.1 2.1 1.7 10.6 3.4
SE 0.5 0.2 0.2 0.3 13.8 0.2 0.3 0.2 3.0 0.6
ug-drug/g-tiss/ug-rel 0.02 0.02 0.01 0.01 0.22 0.01 0.01 0.01 0.06 0.02
SE 0.003 0.001 0.001 0.002 0.074 0.001 0.002 0.001 0.016 0.003
ug-drug/ug-rel 0.11% 0.10% 0.08% 0.08% 0.26% 0.09% 0.08% 0.06% 0.26% 0.11%
SE 0.01% 0.01% 0.00% 0.00% 0.06% 0.01% 0.01% 0.01% 0.07% 0.01%
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TABLE 5:
TABLE 7: Summary of ABT-578 Deposition in the Iliac Arteries (at 14 DAYs)
0 (Overcoat Stents) NO (No-Overcoat Stents)
Summary artery adv prox dist artery adv prox dist
ug-drug/g-tiss 233 1 5 11 23 1 12 4
SE 102 0 1 3 7 0 8 1
ug-drug/g-tiss/ug-
rel 2.5 0.0 0.1 0.1 0.2 0.0 0.1 0.0
SE 1.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0





TABLE 8: Summary of ABT-578 Deposition in Solid Organs (at 14 DAYs)
Sumary - brain liver kidney spleen carotid gonad heart lung intest Ave
ug-drug/g-tiss 0.32 0.34 1.64 0.50 2.65 0.43 0.35 0.64 0.55 0.83
SE 0.05 0.02 1.31 0.03 1.16 0.10 0.07 0.16 0.10 0.22
ug-drug/g-tiss/ug-rel 0.002 0.002 0.011 0.003 0.016 0.003 0.002 0.004 0.004 0.005
SE 0.000 0.000 0.009 0.000 0.005 0.001 0.001 0.001 0.000 0.001
ug-drug/ug-rel 0.010% 0.010% 0.045% 0.013% 0.017% 0.011% 0.010% 0.016% 0.014% 0.016%
SE 0.001% 0.002% 0.036% 0.000% 0.003% 0.004% 0.003% 0.006% 0.001% 0.004%
Sumar - NO brain liver kidney spleen carotid gonad heart lung intest Ave
ug-drug/g-tiss 0.65 0.70 0.47 0.38 0.98 0.36 0.40 0.51 1.09 0.62
SE 0.18 0.29 0.03 0.04 0.51 0.05 0.04 0.06 0.36 0.08
ug-drug/g-tiss/ug-rel 0.004 0.003 0.003 0.003 0.004 0.003 0.003 0.004 0.010 0.004
SE 0.001 0.001 0.000 0.000 0.002 0.002 0.001 0.002 0.010 0.001
ug-drug/ug-rel 0.016% 0.013% 0.012% 0.010% 0.016% 0.014% 0.014% 0.015% 0.042% 0.017%




Ave released 95.9 95.9%
SE 1.4 1.4%
Summary of ABT-578 Deposition in the Iliac Arteries (at 28 DAYs)
, ~iMO!Fo -(Overcoat Stents)
Summary artery adv prox dist
ug-drug/g-tiss 54 6 11 13
SE 22 3 7 4
ug-drug/g-tiss/ug-rel 0.6 0.1 0.1 0.1









Ave released 96.5 96.5%
SE 0.8 0.8%
NO (No-Overcoat Stents)
artery adv prox dist
16 19 21 50
7 11 6 31
0.2 0.2 0.2 0.5

























brain liver kidney spleen carotid gonad heart lung intest Ave
0.3 0.3 2.2 3.2 13.9 2.5 0.4 10.6 2.8 4.0
0.1 0.0 1.6 2.8 12.7 2.3 0.0 5.7 1.6 1.6
0.002 0.002 0.011 0.017 0.071 0.013 0.002 0.054 0.014 0.021
0.000 0.000 0.008 0.015 0.065 0.012 0.000 0.029 0.008 0.008
0.007% 0.008% 0.053% 0.064% 0.049% 0.038% 0.008% 0.098% 0.043% 0.041%
0.002% 0.001% 0.040% 0.056% 0.038% 0.033% 0.001% 0.061% 0.022% 0.011%
brain liver kidney spleen carotid gonad heart lung intest Ave
3 5 5 0.4 5 4 4 8 1 3.8
2 3 2 0.1 2 3 2 3 0.2 0.8
0.002 0.012 0.029 0.002 0.046 0.035 0.007 0.026 0.005 0.018
0.000 0.011 0.024 0.001 0.001 0.033 0.005 0.020 0.002 0.005
0.008% 0.057% 0.121% 0.009% 0.176% 0.132% 0.033% 0.123% 0.010% 0.074%
0.000% 0.051% 0.103% 0.003% 0.046% 0.121% 0.025% 0.105% 0.002% 0.022%
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Appendix 12: Radiolabeled drug quantification in Rabbit tissues
Purpose: To determine the radioactivity content of rabbit tissues following implantation of drug
coated and radioactively labeled stents into the rabbit iliac arteries.
Background: 3[H]-ABT578 coated stents were implanted into rabbit iliac arteries and were recovered
1-28 days post-implantation.
Procedure: This procedure is valid for rabbit tissue samples, which include:
Brain, Liver, Kidney, Spleen, Carotid artery, Gonad, Heart, Lung, and Intestine.
Step Note
1. Spread a tissue sample on a weighing paper and place
it into a convection oven to dry at 40-450 C for 24hrs.
2. Separate the dried tissue samples from the weighing
paper and weigh the samples.
3. Place • 50mg of every sample into a glass scintillation
vial.
4. Add lmL of Solvable29.
5. Incubate for 1.5-4hrs at 50-600C (swirl occasionally).
6. Cool the samples.
7. Add 0.2mL (in two aliquots) of 30% H20 2 to each vial
and cap loosely.
(steps 7-9 are required for liver samples)
8. Incubate for lhr at 50-600 C.
9. Cool the samples.
10. Add 15mL or more of Hionic Fluor'.
11. Light and temp adapt for at least lhr.
12. Count using LSC.
Use Soluene-3501 for stomach 30 tissue.
Color here becomes dark green.
If done over night, use 40-45' and cap
well.3 1
Foaming will occur. Adding H20 2 in
aliquots should reduce foaming.
Color here becomes yellow.
Color becomes light yellow.
Notes
1. Literature protocols that prepare tissue samples for LSC can be subdivided into the protocol for:
* the liver (requires bleaching by H20 2),
* stomach (requires Soluene-350 as a digesting solution),
* other colored tissues (kidney, heart, spleen, lung, which require bleaching by H20 2, but likely less than
liver), and
* other non-colored tissues (brain, gonad, carotid, and muscle (all of which may not require bleaching).
Digestion: Experience has shown that Solvable is the preferred digesting solution over Soluene-350 for rabbit liver
and other colored tissues. Solvable has been used for all samples in this protocol.
Bleaching: Liver and other colored tissues need to be processed using a bleaching step. Bleaching, for the purpose
of consistency, is used for all samples.
2. If tissue samples are not dried right after animal sacrifice they can be left at a cool room temperature for about a
week without noticeable degradation. For longer than a week, they can be stored in a laboratory fridge.
Adapted from: LSC Sample Preparation by Solubilization (www.packardbioscience.com)
29 Solvable, Soluene-350, and Hionic Fluor are reagents available from Packard Bioscience (www.packardbioscience.com).
30 Stomach tissue is different from intestine.
31 Don't leave in oven for too long and let the samples dry out.
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Step
Appendix 13: Radiolabeled Drug Quantification in the Rabbit Blood
Purpose: To determine the radioactivity content of rabbit tissues following implantation of drug
coated and radioactively labeled stents into the rabbit iliac arteries.
Background: 3[H]-ABT578 coated stents were implanted into rabbit iliac arteries and were recovered
1-28 days post-implantation.
Procedure: This procedure is valid for rabbit blood samples, which are less than 0.5mL in volume.
Step
1. Place a blood sample into a glass scintillation vial.
2. Add Solvable 32 in 2/1 ratio to blood. Use max
0.5ml blood33 and min 0.4ml Solvable34.
3. Incubate for lhr, at 50-600 C (swirl occasionally).
4. Add 0.3mL (in 0.lmL aliquots) of 30% H20 2 to
each vial and cap loosely.
5. Allow to stand at room temp 15-30min.
6. Incubate lhr, 50-60 0C.
7. Cool samples.
8. Add 15mL of Ultima Gold.
9. Light and temp adapt for at least 1hr.
10. Count using LSC.
Samples in these experiments were counted 3min
each, which gave the counting error less than 5%.
Note
Use less than 0.5ml blood.
Keep blood samples upright.
Solvable neutralizes the color better than
Soluene-350.
Color goes from red to brown/green.
1-1.5hr may not be sufficient for
coagulated blood samples.
If left overnight, use 40-450 C.
Foaming will occur. Adding H20 2 in
aliquots should reduce foaming.
The color here is yellow.
Color becomes light yellow.
Choose sample counting time so that the
counting error is below some desired
percent.
Note
If blood samples are not analyzed right after collected they can be left at a cool room temperature for about a week
without noticeable degradation. For longer than a week, they can be stored in a laboratory fridge. Samples more
than about 1.5 months old may not respond to the bleaching step above and thus would not be analyzable.
Adapted from:
1. Solvable Solubilization Protocols and Performance (accompanied the product)
32 Solvable, Soluene-350, and Ultima Gold are reagents available from Packard Bioscience
(www.packardbioscience.com). For rabbit blood, Solvable is the preferred digesting agent over Soluene-350.
33 The smaller the blood volume, the less intense will be the color of the final solution that needs to be analyzed by
LSC (and the more reliable the count). However at some low blood volume count may become too low and be
affected by noise (which decreases the reliability of the measurement).
34 0.4 ml is the minimum to cover the vial bottom and ensure contact between Solvable and blood.
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Note
